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The genus Mycobacterium consists of more than 190 species 
and belongs to the family of Mycobacteriaceae, order 
Corynebacteriales, phylum/class Actinobacteria, and kingdom 
Bacteria (http://www.dsmz.de/bacterial-diversity/prokaryotic- 
nomenclature-up-to-date).1 Mycobacteria are nonmotile, rod-
shaped bacilli, characterized by an extremely lipid-rich cell 
wall comprising mycolic acids. These long-chain (C-60 to 
C-90) fatty acids make all mycobacterial species “acid-fast” 
as they resist acid-alcohol decolorization following staining 
with phenicated dyes like fuchsine, enabling their microscopic 
detection. Mycobacteria should not be confused with members 
of the closely related genera Nocardia, Corynebacterium, or 
Rhodococcus, which have shorter-chain (C-22 to C-64) mycolic 
acids and can be partially acid-fast.1
Based on phenotypic characters, the genus was proposed in 
1896 by Lehmann and Neuman.2 With the advent of DNA-based 
analysis, mycobacterial species were initially differentiated 
at <70% similarity by DNA-DNA hybridization,3 and later by 
<98.8% 16SrRNA Sanger sequence similarity4 with or without 
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inclusion of additional housekeeping genes like hsp65 or rpoB.5 
These phenotypic and genotypic analyses are all in agreement 
with the initially described genus Mycobacterium, phylogeneti-
cally distinguishing five major groups.
Recently, the taxonomy of the genus Mycobacterium has 
been challenged based on a core protein analysis—identifying 
insertions/deletions of amino acids, or proteins exclusively 
found in evolutionarily-related groups of species—suggesting 
to split the genus in five monophyletic groups designated as 
the “Tuberculosis-Simiae,” “Terrae,” “Triviale,” “Fortuitum-
Vaccae,” and “Abscessus-Chelonae” clades.6 The five proposed 
genera exactly overlap the major clades of the classical taxon-
omy. Gupta et al. propose to keep the genus “Mycobacterium” 
for species belonging to the “Tuberculosis-Simiae” clade 
and to introduce four novel genera hosting the nontubercu-
lous mycobacteria (NTM) of the above mentioned clades in 
“Mycolicibacter,” “Mycolicibacillus,” “Mycolicibacterium,” and 
“Mycobacteroides,” respectively. This reclassification has been 
debated and questioned for reasons of methodology and clinical 
relevance.7,8 Tortoli and colleagues argue:
NTM may be diverse in their genetics and biology, but 
they produce remarkably similar disease manifesta-
tions in distinct populations at risk. This uniformity 
and the lessons to be learned from it are important for 
both clinicians as well as the affected patients.
The newly proposed reallocation risks to cause confusion among 
clinicians and clinical microbiologists, while not being beneficial 
for the patient. Also, the novel genus “Mycobacterium” is said to 
include all of the major human pathogens6 but does not comprise 
clinically important species like M. abscessus.9 Regarding the 
methodological approach for this reclassification, while Tortoli 
and colleagues identified minor technical errors (mislabeling 
for some of the sequences used),10 Meehan and colleagues ques-
tioned the correctness of the analysis in a more fundamental way.8 
Analyzing the percentage of conserved proteins (POCP) revealed 
that all 145 tested species in the original Mycobacterium genus 
fell within the 50% boundary of all others, while all 223 tested 
non-Mycobacterium species from the Corynebacteriaceae fam-
ily had <50% POCP to all Mycobacterium species, strongly sup-
porting retention of the classical genus Mycobacterium.8 Given 
the equal taxonomic validity of both classification systems, the 
newly proposed genus and species names can be used as syn-
onyms.7 For sake of clarity in this handbook on clinical practice, 
we will stick to the classical genus “Mycobacterium” and related 
species names in this chapter.
With their generation time varying from 2 to 48 hours, myco-
bacterial species can be classified as slow growers—requiring 
more than 7 days to form visible colonies on solid medium—
and rapid growers exhibiting visible growth in less than 7 days. 
This growth-rate-based separation is supported by phylogenetic 
trees constructed from 16S rRNA or whole genome sequences.11 
Combining growth rate with ability to produce pigmentation 
and clinical significance, Runyon classified members of the 
Mycobacterium genus into five groups,12,13 a classification that is 
barely used nowadays.
According to their infectiousness, mycobacteria are classi-
fied in three categories: (1) strict pathogens, with members of 
the M. tuberculosis complex (MTBc) and M. leprae having the 
biggest public health impact; (2) opportunistic pathogens like 
M. avium, that are found in the environment and may cause dis-
ease in persons with predisposing conditions or compromised 
immunity; and (3) saprophytes like M. gordonae, that are ubiq-
uitous and can be found in environmental sources, yet rarely or 
never cause infection and are considered overall nonpathogenic. 
Most (opportunistic) pathogenic mycobacteria are slow growers.
Clinical Importance of Mycobacteria
The clinical importance of mycobacteria cannot be overem-
phasized, especially for members of the MTBc, M. leprae, 
M. ulcerans, and some opportunistic NTM in specific vulnerable 
populations.
Mycobacterium tuberculosis Complex (MTBC)
Tuberculosis (TB) is caused by members of the M. tuberculo-
sis complex (MTBC) comprising M. tuberculosis sensu stricto, 
M. africanum, M. bovis, M. canettii, M. caprae, M. microti, 
M. mungi, M. pinnipedii, M. orygis, and M. surricatae.14 While 
M. tuberculosis and M. africanum are human-adapted species, 
the other species prefer (specific) animal hosts with possible zoo-
notic spill over to humans, mostly from M. bovis via cattle.14 An 
attenuated strain of M. bovis, M. bovis BCG (Bacille Calmette-
Guérin), is used as a vaccine in many high-burden countries to 
protect against acquiring TB, though its efficacy is questionable.15
The two human-adapted species comprise eight phylogenetic 
lineages (L1–L8),16 with L1–L4 and L7–L8 being M. tuberculo-
sis sensu stricto, and L5 and L6 M. africanum. As for their geo-
graphic repartition, L2 and L4 are the most widespread, while L1 
and L3 are intermediately distributed, L5 and L6 are restricted to 
West Africa, and L7 is found only in Ethiopia.17 M. africanum is 
responsible for up to 40% of TB in West Africa.18
Worldwide, TB is among the top 10 causes of death, and the 
first cause of death by a single infectious agent (above HIV/
AIDS).19 It was estimated that in 2018, worldwide, 10 million 
people developed TB, of whom 1.2 million died. Two-thirds of 
cases occurred in eight high-burden countries, with India (27%) 
and China (9%) ranking first. Only 6% of global cases were in 
the World Health Organization (WHO) European Region (3%) 
and the WHO Region of the Americas (3%). In terms of TB inci-
dence, Africa ranked first with 231 per 100,000 population, which 
is almost twofold the worldwide incidence (132 per 100,000 pop-
ulation).19 Likewise, the highest TB mortality rate was reported 
from Africa, where the TB epidemic is fueled by the HIV/AIDS 
epidemic. People living with HIV are 20–30 times more likely to 
develop active TB disease than people without HIV. Following 
huge TB control efforts, increased accessibility to antiretroviral 
treatment and availability of new anti-TB drugs, the worldwide 
TB incidence rate is falling at about 2% per year, with the fastest 
regional declines between 2013 and 2017 in the WHO European 
(on average, 5% per year) and African (3.8% per year) regions.19 
Nevertheless, TB continues to be a major public health problem 
in many countries.
Of added importance is the number of MTBC strains that 
are found resistant to one or more of the antitubercular agents. 
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TB disease is always treated with a combination therapy. The pre-
ferred regimen for treating adults with TB consists of an intensive 
phase of 2 months of isoniazid (INH), rifampin (RIF), pyrazin-
amide (PZA), and ethambutol (EMB) followed by a continuation 
phase of 4 months of INH and RIF. RIF, a strong bactericidal and 
sterilizing drug, is considered the core drug for standard TB treat-
ment.20 Patients infected with MTBC strains resistant to (at least) 
RIF or RIF and INH—defined as multidrug resistant (MDR)—
should be treated with alternative drugs in so-called MDR-TB 
regimens. While these drugs are commonly known as “second-
line” drugs, recent guidelines from the WHO classify these drugs 
in group A, B, and C.21 Individualized MDR-TB regimens using 
three drugs from group A, complemented by one or two drugs 
from group B, and one or more from C, have been proposed for 
a duration of 18 months or more.22 Alternatively, a standardized 
short MDR-TB regimen (9–12 months) has been shown to be 
noninferior compared to the long regimen,22 and was success-
fully implemented under programmatic conditions in multiple 
African and Asian countries.23,24 The short regimen includes a 
fourth-generation fluoroquinolone (gatifloxacin, moxifloxacin, or 
levofloxacin) as core drug.20 Recently, the use of injectable ami-
noglycosides (amikacin or kanamycin) or polypeptides (capreo-
mycin) has been discouraged, due to the irreversible ototoxicity.21
An MDR patient may further develop resistance to other drugs 
during the course of treatment. MDR combined with resistance 
to a fluoroquinolone and an injectable aminoglycoside or poly-
peptide is defined as extreme drug resistance (XDR). XDR-TB 
treatment regimens require further inclusion of less efficient, 
more toxic group C drugs21 or new drugs like bedaquiline and 
delamanid. XDR-TB treatment is difficult and costly.
MDR- and XDR-TB are a major concern worldwide, with cases 
reported in all countries. According to the WHO, in 2018, glob-
ally 3.4% of new cases and 18% of previously treated TB cases 
had RIF-resistant/MDR disease, with three countries account-
ing for half of the world’s cases of RIF-resistant/MDR-TB: India 
(27%), China (14%), and the Russian Federation (9%).19 Among 
MDR cases 6.2% were estimated to be XDR, numbers that were 
slightly lower compared to 2018 data.19
Non-tuberculous Mycobacteria (NTM)
Mycobacterial species different from MTBC are grouped as 
NTM, also referred to as atypical or anonymous mycobacteria, 
or mycobacteria other than tuberculosis (MOTT).
Humans can acquire NTM infection from various sources in 
the environment such as natural and engineered water systems, 
mist, aerosols, dust, and soil,25 or from contact with plants, birds, 
fish, and other animals.26,27 In humans, NTM can be found as 
colonizers without clinical relevance—with chronic lung disease 
as predisposing factor—or they can be seen as mostly intracel-
lular pathogens. Human-to-human transmission of NTM was not 
known to be a common route of transmission, till recent evidence 
documented human-to-human transmission in cystic fibrosis 
patients.28–30
While the frequency of clinical isolation of NTM is increas-
ing in many countries with decreasing MTBC prevalence,27,31–33 
and even in countries endemic for TB,34,35 their clinical relevance 
remains often unclear.
The diagnosis of NTM disease remains a clinical dilemma for 
clinicians as NTM exist in the environment, and mere isolation 
from an unsterile site could be a reflection of environmental con-
tamination. Correctly identifying and determining the clinical 
relevance are however paramount, as the time-consuming and 
complicated treatment of NTM disease will vary depending on 
the species. NTM infections most commonly manifest as pul-
monary disease (especially in adults), followed by skin and soft 
tissue infections, lymphadenitis (especially in children), or dis-
seminated disease in severely compromised patients.36
General criteria for the diagnosis of pulmonary NTM disease 
as established by the American Thoracic Society (ATS) may 
guide on clinical decision-making.37 One of the criteria states 
that two positive cultures should be obtained from subsequent 
sputum specimens OR a single positive culture from a bronchial 
aspirate. Nevertheless, single-sputum NTM isolation can provide 
evidence of true NTM-lung-disease, taking into account patient’s 
characteristics like bronchiectasis, younger age, and more severe 
radiographic pulmonary lesions.38
It is to be noted that only around 20–25% of patients with 
pulmonary NTM isolates meet the ATS criteria,32,35,39,40 which 
can increase up to 60% among patients at higher risk like cystic 
fibrosis patients.41 Of note, a considerable proportion of patients 
with NTM pulmonary disease in Europe have no detected under-
lying lung disease or immunodeficiency.42 In the United States, 
the annual rates of pulmonary NTM disease range from 1.4 to 
13.9 per 100,000 inhabitants,43 while in Europe rates seem to be 
lower ranging from 0.2 to 2.9 per 100,000 population.42
The probability of clinical relevance varies across species. 
NTM commonly found in patients with pulmonary symptoms are 
M. avium, M. intracellulare, M. kansasii, M. xenopi, M. absces-
sus, M. fortuitum, and M. scrofulaceum.32,36,40,44 M. abscessus 
is increasingly seen as pulmonary pathogen.39,40 While the less 
common M. genavense has a very high likelihood of being clini-
cally relevant in pulmonary disease, M. avium and M. kansasii 
have a moderate odds, and M. gordonae is almost never involved 
in disease though frequently being isolated.32,40 The frequency 
of isolated NTM species may vary across geographical regions 
and settings.45 Also, the relative frequency of NTM species may 
change over time, as has been noticed in Europe with shifts of 
M. kansasii and M. malmoense frequency.42
Regarding extra-pulmonary NTM disease, the majority of 
lymphadenitis cases are seen in young children, and most often 
caused by M. avium, M. scrofulaceum, M. simiae, M. haemophi-
lum, M. malmoense, or M. marinum.32,46-48
NTM species most commonly reported from skin and soft 
tissue infections are M. fortuitum, M. abscessus, M. chelonae 
among the rapidly growing mycobacteria, and M. marinum, 
M. ulcerans, M. chimaera, and M. haemophilum as slowly grow-
ing species.27 Using inadequately disinfected medical equipment 
has been associated with outbreaks of NTM skin and soft tissue 
infections. Because of their lipophilic character, environmental 
mycobacteria are frequently found in biofilms, making them 
even more resistant to decontamination with standard antiseptics 
and biocides, including chlorhexidine and glutaraldehyde.42,49 
Recently, some compounds have been described to be active 
against NTM in biofilms.50,51 Potable water systems have been 
proposed as an advantageous pre-infection niche for bacteria—
including NTM-colonizing lungs of CF patients.52 In a recent 
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comparison of Norwegian chlorinated and non-chlorinated 
drinking water distribution systems, it was found that residual 
chloramine may increase mycobacterial biomass, while it may 
also decrease mycobacterial diversity.53 As a result, mycobacte-
rial species have been associated with both pseudo-outbreaks 
and real outbreaks of nosocomial infections following surgery 
or cosmetic procedures. In the United States, cosmetic surgery 
tourism constitutes an increased risk for NTM soft skin tissue 
disease.54,55 Molecular typing of the isolated strains during an 
outbreak with M. abscessus after breast augmentation surgery 
in Venezuela undoubtedly identified tap water as the source of 
infection.56 Also from nonhospital/cosmetic settings, outbreaks 
have been reported, such as M. marinum infections following 
fish handling57 or use of premixed ink as the common source of 
infection with M. chelonae.58
The NTM commonly found as causative agent in patients with 
disseminated disease are M. avium, M. intracellulare, M. kansa-
sii, M. haemophilum, and M. chelonae.36,59
M. gordonae and M. engbaekii are among the NTM most 
frequently found as contaminants with no or very rare clinical 
implication.
Trying to ascertain the  prevalence  of NTM disease may be 
complicated by several factors. As opposed to TB, NTM disease 
is not notifiable to public health authorities at a national or an 
international level, with a few exceptions such as Oregon State 
(the U.S.A). Therefore, underreporting might occur, which can 
prohibit collection of systematic data and potentially lead to an 
underestimation of NTM disease. Conversely, overdiagnosis may 
occur when patients are diagnosed with (and treated for) non-
pathogenic mycobacteria, and in those cases in which the clini-
cal relevance of the potential pathogenic mycobacterium isolated 
has been misjudged. Finally, care must be taken with regard to 
the trend analysis of certain species, as the degree of taxonomi-
cal diversification is much higher in contemporary studies using 
molecular identification techniques, than it is in older studies 
based on phenotypic characteristics.42
Clinically Significant Species 
of Slowly Growing NTM
The following are some of the most important slow-growing 
NTM species that have been associated with clinical disease. An 
overview of the clinical relevance for additional slowly grow-
ing NTM species can be consulted at https://bccm.belspo.be/
about-us/bccm-itm.
Mycobacterium leprae
This mycobacterium is an obligatory intracellular pathogen and 
the causative agent of leprosy or Hansen’s disease. The disease 
mainly affects the skin, the peripheral nerves, mucosa of the 
upper respiratory tract, and the eyes. It can range from mild and 
self-limiting (tuberculoid type) to severely debilitating (leproma-
tous type). Leprosy is also classified as paucibacillary (PB) or 
multibacillary (MB), based on the number of skin lesions and the 
presence of nerve involvement. It is an ancient disease with cases 
depicted around 600 BC. There has always been a large social 
stigma associated with leprosy, which resulted in victims being 
segregated to leper colonies.
In humans, M. leprae is a very slow-growing organism with 
a long incubation period, it can take from 6 months to 20 years 
for an infected individual to develop symptoms after exposure 
(WHO fact sheet). M. leprae does not grow on laboratory media, 
likely due to the loss of important genes, with a reduced genome 
size of 3.3 Mbp compared to the 4.1 Mbp of MTBC.60
In its efforts to eliminate leprosy, the WHO recently introduced 
the concept of “one report for leprosy” by launching an online 
data collection tool to facilitate the gathering of epidemiological 
and programmatic indicators from member states. In 2018, there 
were 208,619 new leprosy cases registered globally, according to 
official figures from 159 countries from the six WHO Regions 
(https://www.who.int/news-room/fact-sheets/detail/leprosy). The 
majority of these cases were found in nine countries in Asia, 
Africa, and Latin America. In the United States, leprosy is seen 
in about 200 new cases every year, with nine-banded armadillos 
being an important reservoir.61
Current diagnosis of leprosy relies often solely on clinical find-
ings, without microbiological confirmation. Microscopy for detec-
tion of acid-fast bacilli can confirm the diagnosis of more advanced 
leprosy, but it is less effective in the early stages or in paucibacil-
lary cases. Nucleic acid-based detection techniques for M. leprae 
are becoming a standard of care for supporting the diagnosis of 
leprosy, with the repetitive sequence RLEP as a promising target 
for qPCR, allowing the detection of approximately one M. leprae 
genome in a sample (https://internationaltextbookofleprosy.org/
chapter/pathogen-detection). No commercial molecular tests for 
M. leprae detection are available.
Clinical diagnosis of leprosy is based on the presence of at 
least one of three cardinal signs: (1) definite loss of sensation in 
a pale (hypopigmented) or reddish skin patch; (2) thickened or 
enlarged peripheral nerve with loss of sensation and/or weakness 
of the muscles supplied by that nerve; or (3) presence of acid-fast 
bacilli.62
Leprosy is now totally treatable with a free-of-cost multidrug 
therapy including dapsone, RIF, and clofazimine.
Mycobacterium ulcerans
This species is a close relative to M. marinum, but differs in 
its ability to produce a mycolactone toxin. It is the causative 
agent of Buruli ulcer (BU), a disease which occurs in at least 
33 countries with mostly tropical and subtropical or temperate 
climates. Most cases are reported in West and Central Africa, 
while Australia remains an important non-African endemic 
country. In 2018, 2,713 suspected BU cases were reported 
from 14 countries, confirming the recent increase after years 
of decline from 2010 (5,000 cases) to 2016 (1,961 cases). The 
reasons for the initial decline and recent increase remain 
unclear https://www.who.int/news-room/fact-sheets/detail/
buruli-ulcer-(mycobacterium-ulcerans-infection).
The disease begins as a painless nodule, but if left untreated, 
can progress to a debilitating skin ulcer or osteomyelitis, and 
can lead to permanent disfigurement and long-term disability.63 
It is the mycolactone that causes subcutaneous tissue destruc-
tion and local immunosuppression, aggravating the symptoms. 
Most of the lesions appear on the limbs, especially on the lower 
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extremities.63 M. ulcerans is an environmental bacterium, and 
the exact means of transmission remain unknown, but most 
infections appear to be found adjacent to bodies of (stagnant) 
water. There is some indication that mosquitoes may be respon-
sible for transmission of the disease in Australia,64,65 although 
evidence of M. ulcerans positive mosquitoes remains limited.66 
In Africa, where BU is most prevalent, no environmental source 
has been identified so far, with one exception of a M. ulcerans 
isolate grown from a water strider in Benin.67
Although the disease can often be diagnosed on clinical pre-
sentation, this organism can grow on standard media suitable for 
mycobacterial growth, with a growth temperature optimum of 
30°C. The most sensitive diagnosis for BU, however, is done by 
PCR targeting the insertion sequence IS2404.
Buruli ulcer is treatable with combination therapy using RIF 
and clarithromycin for 8 weeks. Surgical debridement is often 
required as well, especially for larger ulcers or advanced disease.63
Mycobacterium avium Complex (MAC)
Originally, M. avium and M. intracellulare were the only two spe-
cies belonging to the Mycobacterium avium complex (MAC).37 
Sequencing studies of the 16S rRNA gene and 16S–23S internal 
transcribed spacer (ITS) confirmed the MAC as a diverse, yet 
relatively clearly defined and clustered group among the slowly 
growing NTM, comprising the species M. avium, M. intracel-
lulare* (including M. chimaera*, M. yongonense*, M. para-
intracellulare*), M. colombiense, M. arosiense, M. vulneris, 
M. bouchedurhonense, M. timonense, M. marseillense, and M. 
lepraemurium.68–70
M. intracellulare cannot be easily differentiated from 
M. avium through traditional physical and biochemical tests;37 it 
requires genetic analysis.
Members of the MAC are ubiquitous in soil and many natu-
ral and man-made water systems.25,71,72 Although usually not 
considered pathogenic in the general community, these organ-
isms are the most commonly isolated causative agents of NTM-
mediated lung disease with TB-like symptoms,37,70 and they 
may cause lymphadenitis in children and/or other extrapulmo-
nary and disseminated infections in immunocompromised pati
ents.37,68,73 Pulmonary disease attributed to the MAC is mainly 
caused by M. avium and M. intracellulare. Other MAC species 
have been increasingly reported as potential causative agents 
of NTM lung infections, but their full spectrum of diseases is 
not yet entirely known.68 One member of the MAC, namely 
M. lepraemurium, is known as the etiologic agent of feline and 
murine leprosy.74,75
Infections are most probably acquired by inhalation or inges-
tion of the MAC species. Although frequently isolated from 
respiratory specimens, isolation of MAC does not necessarily 
imply clinical relevance in pulmonary disease.37
To date, there is still an ongoing debate on whether or not 
specific species should be assigned within the complex or if 
the MAC should be considered as a single entity. Moreover, the 
American Thoracic Society and Infectious Diseases Society of 
America (ATS/IDSA) stated that although the differentiation 
between M. avium and M. intracellulare may be important epi-
demiologically for research purposes and in the future for thera-
peutic use, the distinction is not yet clinically significant enough 
to routinely identify MAC isolates to the species level.37 Also, 
disease caused by all members of the MAC is treated in a similar 
manner using a regimen specific to the MAC.68
Treatment regimens for MAC infections include combination 
therapy, typically with a macrolide (clarithromycin or azithro-
mycin) as core drug, with RIF (or another companion drug), 
EMB and occasionally amikacin in cases of disseminated dis-
ease when a more aggressive therapy is required.37,76 ATS recom-
mends clarithromycin susceptibility testing for new, previously 
untreated MAC isolates.37
Mycobacterium avium
M. avium was originally divided into three subspecies cor-
responding to pathogenicity and host-range characteristics: 
M. avium avium, M. avium paratuberculosis, and M. avium 
silvaticum.77,78 To elucidate the epidemiology of  M. avium-
associated disease, Mijs et al. clustered the isolates originating 
from humans and pigs together as a suggested fourth subspe-
cies called M. avium hominissuis,79 the most abundant etiological 
agent of M. avium-related disease in humans.80,81 Additionally, 
Mijs and colleagues stated that the designation M. avium avium 
should be reserved for bird-type strains because of its associa-
tion with avian TB.79 M. avium paratuberculosis on the other 
hand is the causative agent of Johne’s disease resulting in chronic 
granulomatous enteritis of ruminant livestock and wildlife and 
may have a similar—yet not proven—role in Crohn’s diseases 
in humans.82-84 Finally, M. avium silvaticum is highly related 
to M. avium avium and has been isolated primarily from wood 
pigeons wherein it can cause TB-like lesions.78
Tortoli and colleagues suggest combining these M. avium sub-
species within a single taxon, and to regard them as synonyms 
based on their very high average nucleotide identity (ANI) and 
genome-to-genome distances (GG) values well exceeding the 
subspecies thresholds.85 In consideration of their adaptation 
to specific hosts, the previously named subspecies should be 
reclassified as variants.85 Subspecies status of M. avium para-
tuberculosis is proposed to be maintained due to the significant 
differences in clinical presentation between this subspecies and 
other variants of the MAC.77,85
This would result in M. avium variant avium, M. avium vari-
ant hominissuis, M. avium variant silvaticum, and M. avium 
paratuberculosis
M. avium grows at 30–37°C on media suited for mycobacte-
rial growth. Primary isolation of both M. avium paratuberculo-
sis and M. silvaticum requires adding mycobactin to the culture 
medium.86 Besides, M. silvaticum is unable to grow on egg media 
and needs the stimulation of growth by pyruvate and at pH 5.5, 
gradually losing this phenotype upon subculture.78
Mycobacterium intracellulare and 
Closely Related Species
This mycobacterium is mainly a respiratory pathogen in humans, 
responsible for most MAC lung diseases in the United States, while 
an association with disseminated disease is less common.35,77
M. chimaera became well known for its association with con-
taminated heater-cooler devices used in open heart surgery dur-
ing a worldwide outbreak.87,88
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M. yongonense and M. chimaera were recently reclassified 
as subspecies of M. intracellulare, resulting in the designation 
of three new taxa: M. intracellulare intracellulare, M. intracel-
lulare yongonense,89 and M. intracellulare chimaera.69 In 2019, 
M. intracellulare chimaera has even been proposed as synonym 
of M. intracellulare yongonense.85
Likewise, M. paraintracellulare90 was proposed to represent a 
fourth subspecies or even a synonym of M. intracellulare rather 
than a separate species based on its average nucleotide identity 
(ANI) value being well within intraspecies values.68,69 Also, the 
need to distinguish M. paraintracellulare from M. intracellulare 
is questioned as there is no reason of clinical relevance to do so.68
This would result in a new taxonomy to recognize only a single 
species, M. intracellulare, with two subspecies: M. intracellu-
lare intracellulare and M. intracellulare chimaera.85
Mycobacterium haemophilum
This organism was first isolated in 1978 from a patient with 
Hodgkin’s disease, and it was shown to cause skin lesions and 
disseminated infections in patients with AIDS in the early- to 
mid-1990s. Indeed, M. haemophilum has been described in 
immunosuppressed patients, including those with lymphoma, 
those who undergo bone marrow or cardiac transplantation, and 
patients receiving steroid therapy.91 It has also been described as 
a cause of lymphadenitis in immunocompetent children.92
The growth requirement of these organisms is rather unique 
among mycobacteria as they require hemin or ferric ammonium 
citrate for growth, at an optimal temperature of 30°C.93 This 
probably accounts for the relative infrequency of its isolation, 
especially in laboratories solely relying on culture at 37°C. It is 
advisable that all patients presenting with a skin lesion have their 
specimen cultured onto medium containing a source of hemin 
with incubation at 30°C.
There is no standard therapy for infections with M. haemophi-
lum but regimens including clarithromycin, doxycycline, cipro-
floxacin, amikacin, INH, and RIF have led to resolution of the 
disease,94 while surgical intervention may be favored in case of 
cervicofacial lymphadenitis.95
Mycobacterium kansasii
This mycobacterium causes a disease that resembles pulmonary 
TB. The patients present with cough, fever, and night sweats as is 
seen in TB.96 Typically, the patient is an older male with a prior 
history of TB, chronic obstructive pulmonary disease or other 
chronic lung diseases. Cavitary disease may be seen on x-ray. 
Extra-pulmonary disease caused by M. kansasii has also been 
described occasionally.59,97 The odds of clinical significance for 
a positive M. kansasii culture is relatively high.32 In a Korean 
study, 52% of all patients with M. kansasii respiratory isolates 
exhibited clinically significant disease.98
In the past, seven subtypes of M. kansasii have been reported 
based on target sequences such as hsp65. Recent WGS analyses 
support a reclassification of this polyphyletic group in separate 
species rather than subtypes,99,100 with clearer separation of their 
clinical relevance (Table 33.1).
M. kansasii has similar growth conditions as M. tuberculosis. 
Standard treatment involves the use of first-line anti-TB drugs 
RIF, INH, and RMB, while RIF-resistant M. kansasii treatment 
can be based on drug-susceptibility testing data.29
Mycobacterium malmoense
This mycobacterium is rarely seen in the United States but is 
recognized as causing pulmonary disease in Northern Europe, 
with a frequency exceeding that of M. kansasii-isolation in some 
UK settings. In the United Kingdom, M. malmoense isolates 
had a moderate chance of being clinically significance,40 while 
in the Netherlands M. malmoense was found to be clinically 
relevant at much higher (80% of cases) levels. These usually 
cause pulmonary disease with serious morbidity.101 The typical 
patient is a male over his 50s with prior or underlying lung dis-
ease.101,102 There have also been reports of—mostly pediatric—
lymphadenitis caused by M. malmoense.101,103
M. malmoense has no specific growth requirements—even 
though growth on solid medium can remain very slight, with 
good growth at 37°C.104
Therapy includes the use of RIF and EMB, supplemented with 
a macrolide,29 although some studies showed no additional bene-
fit of adjunctive clarithromycin.101,105
Mycobacterium xenopi
Like most of the other slowly growing opportunistic pathogenic 
NTM, this species causes pulmonary disease, with various pre-
sentations (cavitary, nodular, or diffuse infiltrate).106 M. xenopi 
disease has become prominent in Northern European and 
American countries with a low TB prevalence, yet is rarely or 
not seen in TB high prevalent countries (China,107 Tanzania,34 
and Mozambique35). Nevertheless, M. xenopi is a fairly ubiqui-
tous environmental bacterium found mostly in water, including 
the water supplies of hospitals. The typical patient is an older 
male with a prior history of TB or other lung disease. The patient 
often presents with cavitary lung disease. The probability of 
being clinically relevant was found to be moderate 40–60%.3239,40
This organism is easily grown in culture but prefers an ele-
vated growth temperature (42°C) and forms typical “bird’s nest” 
colonies when grown on solid media.108
M. xenopi disease is hard to treat with around 30% success 
rate.109 Variable success has been reported using a four-drug 
TABLE 33.1










M. kansasii 1 Most pathogenic Frequent
M. persicum 2 Pathogenic Limited data
M. pseudokansasii 3 Rarely pathogenic Frequent
M. speciesa 4
M. innocens 5 Rarely pathogenic Limited data
M. attenuatum 6 Nonpathogenic Very rarely
No suggestionb 7
a To be defined as soon as a Type strain is available; bLack of Type strain and 
full genome.
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regimen comprising RIF, EMB, a macrolide (clarithromycin or 
azithromycin), and a fluoroquinolone (cipro- or moxifloxacin) 
or INH.29,106 For severe disease an injectable aminoglycoside 
(amikacin or streptomycin) can be added.29
Mycobacterium celatum
This mycobacterium was first described in the early 1990s as a 
causative agent of disseminated disease in AIDS patients with 
a very low CD4 count.110 Subsequently, M. celatum has been 
identified as a cause of pulmonary disease in immunocompetent 
individuals as well, with disease resembling that of MTBC and 
other NTM species.111 M. celatum isolates can be easily mis-
identified as M. xenopi, sharing many biochemical/phenotypic 
characteristics including a typical fatty acid pattern.112 M. cela-
tum can be differentiated from M. xenopi by its poor growth at 
45°C, and production of larger colonies on 7H10 agar.112 Using 
the AccuProbe assay—which detects MTBC-specific nucleic 
acids—M. celatum isolates can be falsely positive.113
There is no standard therapy for infections with M. celatum. 
Isolates of M. celatum are generally resistant to RIF. Successful 
treatment has been achieved by combining clarithromycin, EMB, 
and ciprofloxacin.114
Mycobacterium marinum
Mycobacterium marinum was first observed in 1926 caus-
ing infections in saltwater fish in the Philadelphia aquarium.115 
The first reported cases in humans were from an epidemic in 
Sweden in 1954. These patients, who all swam in the same swim-
ming pool, developed lesions, which began as papules at the 
site of infection and mostly became ulcerated and/or exudative. 
M. marinum disease, often referred to as “swimming pool granu-
loma,” has also been associated with fish tank ownership.116 The 
infection usually occurs on the upper extremities, including the 
hands, where the organism gains entrance through scratches and 
abrasions, and generally remains localized at the site of infection.
M. marinum can be cultured on standard media used for 
mycobacterial growth, but with incubation at 30°C, the optimum 
growth temperature for this species.
Therapy with regimens containing EMB, RIF, clarithromycin, 
amikacin, or doxycycline is usually effective. In some instances, 
surgical intervention is required.117
Clinically Significant Species 
of Rapidly Growing NTM
At present, rapidly growing mycobacteria comprise approximately 
50% of all recognized and validated species belonging to the 
genus Mycobacterium.118,119 Although ubiquitous in environmen-
tal reservoirs, some rapidly growing NTM are frequently isolated 
in healthcare facilities and have emerged as important human 
pathogens.120 They are commonly found in abscesses formed after 
an unintentional inoculation or puncture wound, through contam-
ination of surgical wounds or via traumatic injuries.27 M. absces-
sus is increasingly seen as pulmonary pathogen.39,40 M. abscessus, 
M. chelonae, and M. fortuitum together embody more than 80% 
of clinical isolates of rapidly growing NTM.119,121
First-line TB drugs are ineffective against NTM disease due 
to rapid growers.
An overview of the clinical relevance for additional rapidly 
growing NTM species can be consulted at https://bccm.belspo.
be/about-us/bccm-itm.
Mycobacterium abscessus
This organism was first identified in 1952 by Moore and Frerichs, 
who isolated it from a patient’s  knee abscess.122 Species name 
designation was based on the mycobacterium’s ability to cause 
human skin and soft tissue infection, producing deep subcutane-
ous abscesses.123
Over time,  M. abscessus’ taxonomy, particularly the identi-
fication of  species and subspecies, has faced many challenges 
resulting in a cumbersome cascade of nomenclature changes. 
M. abscessus and M. chelonae were originally considered to be 
the same species as they present almost identical biochemical 
features.10,121,123 After first being designated subspecies status in 
1972,124 Kusunoki and Ezaki re-elevated M. abscessus to species 
status in 1992 based on genomic DNA hybridization studies.125 
As a result, M. chelonae  subspecies  chelonae  was also rein-
stated again to its former name M. chelonae. After M. absces-
sus  was recognized as a distinct species, the mycobacterium 
has been further categorized into three distinct subspecies: M. 
abscessus abscessus, M. abscessus bolletii, and M. abscessus 
massiliense.126-128
Precise identification to subspecies level of the disease-causing 
strain in M. abscessus pulmonary infections is essential for diag-
nosis and management as the subspecies differ in clinical disease 
presentation as well as in susceptibility to drugs and in optimal 
therapeutic regimens.129 M. abscessus abscessus and M. absces-
sus bolletii have an erm (erythromycin ribosomal methylase) 
gene that confers inducible macrolide resistance, whereas most 
M. abscessus massiliense strains have a dysfunctional erm 
gene, resulting in macrolide susceptibility.130 Consequently, 
better treatment outcomes have been reported in patients with 
M. abscessus massiliense pulmonary infection than those with 
M. abscessus abscessus disease.131
M. abscessus abscessus is the most common pathogen of the 
three M. abscessus subspecies,132 and typically it is associated 
with a wide range of skin and soft tissue infections in human 
hosts,37,123,133 while being increasingly the cause of pulmonary 
infections in patients with underlying structural lung disease 
such as cystic fibrosis and bronchiectasis.134
Skin and soft tissue infections often develop after the use of 
equipment or injected substances contaminated with these rapid 
growing mycobacteria during medical, cosmetic, and plastic 
surgery (such as liposuction,135 mammaplasty,56 and mesother-
apy136), pedicures,137 and after trauma.138,139 Also pseudoinfec-
tions due to contaminated bronchoscopes and endoscopes have 
been ascribed to M. abscessus140 and M. abscessus bolletii.141
M. abscessus is a nonchromogenic rapidly growing NTM 
characterized by its inability to grow at 42°C.
Current guidelines recommend an initial treatment for 
2–4 months consisting of two parenteral intravenous agents 
(such as amikacin, cefoxitin, imipenem, and tigecycline) and a 
macrolide antibiotic if the species is macrolide susceptible.37,133 
If not, the macrolide should be replaced by another agent based 
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on in vitro drug susceptibility testing data. Secondarily, an addi-
tional inhaled/oral antibiotic (fluoroquinolone, linezolid, or clo-
fazimine) can be added during the continuation phase.133
Mycobacterium chelonae
As stated before, M. chelonae is closely related to M. absces-
sus but lacks the erm gene that confers macrolide resistance in 
M. abscessus.142 M. chelonae is also highly resistant to cefoxitin, 
while M. abscessus  is intermediately susceptible. Additionally, 
M. chelonae is only a rare cause of pulmonary infections and 
instead has a greater preference for skin and soft tissue infec-
tions.27,143 Furthermore, M. chelonae has been associated with 
catheter-related, disseminated and bone infections, mainly in 
immunocompromised patients with risk factors such as organ 
transplantation, renal failure, surgery, long-term corticosteroid 
therapy, or chemotherapy.144,145 Infections of M. chelonae can 
also be linked to ophthalmic surgery such as LASIK (laser in situ 
keratomileusis)146 and cosmetic procedures (inoculations, plastic 
surgery, mesotherapy).147
This species of rapidly growing NTM is abundant in man-
made environments, such as tap water, but has also been 
retrieved from natural environments, such as lakes, freshwater 
rivers, and seas.148 Given its ubiquitous presence in the environ-
ment, exposure to M. chelonae is common and is often seen in 
clinical labs, contaminating solutions, medical equipment, and 
surgical wounds.
M. chelonae grows optimally at 30–32°C.
Treatment regimens of M. chelonae infections may include 
tobramycin, clarithromycin, linezolid, imipenem, or clofazi-
mine. To avoid the development of macrolide resistance, clar-
ithromycin will usually be combined with a second agent.37
Mycobacterium fortuitum Group
In 1938, da Costa Cruz (1938) proposed the name M. fortui-
tum for a strain isolated from a patient with a postinjection skin 
abscess.121 More than 30 years later, Stanford and Gunthorpe 
showed that the isolate was identical to a formerly recognized 
species named  M. ranae, isolated from a frog by Küster in 
1905.149,150 In 1972, the request of Runyon to maintain the species 
designation M. fortuitum was accepted, which to date still stands 
in nomenclature as such.121
The  M. fortuitum  group comprises  the species M. fortui-
tum, M. peregrinum, M. senegalense, M. alvei, M. houstonense, 
M. setense, M. neworleansense,  M. boenickei,  M. septicum, 
M. brisbanense, and M. porcinum,151,152 and its species are com-
monly found in drinking water, water distribution systems, and in 
a variety of soil worldwide.148
In a series of cases of extrapulmonary disease caused by the 
M. fortuitum group, Wallace et al. 153 reported that almost 80% of 
the infections were due to the single species M. fortuitum.
M. fortuitum has also been associated with a number of noso-
comial pseudo-outbreaks,154,155 and it has been linked to surgical 
site infections, skin lesions, postinjection abscesses, otitis media, 
and catheter-related infections.156–160 Whirlpool pedicure foot-
baths in nail salons have also been identified as a potential source 
of M. fortuitum-associated furunculosis.118,161
M. fortuitum grows under the same conditions as MTBC.
Treatment of M. fortuitum infections consists of minimal 
4 months of therapy with at least two agents with in vitro activity 
against the clinical isolate.76 This regimen may include a combi-
nation of amikacin, fluoroquinolones, some tetracyclines, cefoxi-
tin, imipenem, or sulfonamides.153,162,163 In some cases where 
drug therapy is difficult, surgical intervention is required.118
Diagnosis
Clinical suspicion of mycobacterial disease (including x-ray or 
other imaging techniques) can be confirmed bacteriologically.
For decades, smear microscopy to detect acid-fast bacilli (AFB) 
and isolation of mycobacteria by culture were the most important 
diagnostic tools for mycobacterial disease, especially in low-
resource settings where microscopy often was the only available 
and affordable method. Microscopy however lacks sensitivity 
(for pulmonary TB overall around 60% and only 22–43% in 
HIV-positive individuals; 10–60% for clinically significant NTM 
disease),40 while culture is significantly more sensitive (80–95%) 
but can take weeks for M. tuberculosis complex and slowly grow-
ing NTM to become positive. With the advent of nucleic-acid 
amplification techniques in the 1990s, rapid, specific, and sensi-
tive diagnosis became conceivable, but it was mostly restricted to 
well-equipped laboratories in high-income countries. Only with 
the introduction and roll out of the cartridge-based GeneXpert 
MTB/RIF assay (Cepheid, U.S.A), molecular diagnosis for 
TB—with simultaneous detection of rifampicin resistance—
has become widely available and increasingly is the first test of 
choice in TB high prevalent settings.164,165,166 TB-LAMP, another 
relatively easy isothermal DNA amplification assay to detect 
MTBC, has been endorsed in 2016,167 but it has been rolled out in 
only a limited number of settings.168,169
The antigen-detection-based lateral flow-lipoarabinomannan 
(LF-LAM) assay has been recommended to assist in TB diag-
nosis in specific populations, namely adults, adolescents, and 
children living with HIV with signs and symptoms of TB and 
CD4 cell count under 200 in inpatient settings as well as in 
adults, adolescents, and children living with HIV with signs and 
symptoms of TB irrespective of the CD4 cell count in outpatient 
settings.170,171 LAM, a lipopolysaccharide, is present in myco-
bacterial cell walls and is released from metabolically active 
or degenerating bacterial cells. An LF-LAM test is to be done 
manually on a urine sample.170
Regarding serodiagnostics, the WHO strongly recommended 
that commercially available assays should not be used for the 
diagnosis of pulmonary or extra-pulmonary TB.172
Despite progress in molecular diagnosis, culture remains 
important for subsequent phenotypic drug-susceptibility test-
ing (especially for new drugs like bedaquiline), monitoring of 
patients during treatment, and as a gold standard test for most 
mycobacterial diseases. Once a culture becomes positive and is 
confirmed to yield AFB, the isolated bacteria can be identified 
by phenotypic or genotypic means prior to phenotypic drug-
susceptibility testing.
Of note, two test systems are available for the identification of 
latent TB infection: the tuberculosis skin test (TST) and inter-
feron-gamma assays (IGRAs). The TST consists of an intrader-
mal injection of purified protein derivatives (PPD, tuberculin), 
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with a read-out by qualified staff after 48–72 hours. This assay, 
albeit cheap and not requiring any laboratory facility, is not spe-
cific because of cross-reaction due to prior BCG vaccination or 
exposure to NTM.173 Efforts are ongoing to validate new skin 
tests using more specific RD1-antigens, not shared by M. bovis 
BCG, showing similar sensitivity.174,175 IGRAs are in vitro blood 
tests to measure cell-mediated immune response, and make use 
of the same RD1-antigens.173 Both test systems have limited 
value to predict progress to active TB.
Specimen Selection
Respiratory specimens constitute the most common type of 
specimen submitted for the culture and isolation of mycobacte-
ria, with only 10–20% of clinical specimens originating from 
nonpulmonary sites.176 For respiratory infections, sputum is to be 
obtained by preference early in the morning. The patient should 
be instructed to rinse his/her mouth with bottle water (tap water 
is not recommended), and cough up expectorate into a sterile 
sputum collection device specifically designed for mycobacte-
rial culture. Multiple early morning sputum samples improve the 
chances to grow mycobacteria, especially NTM. If the patient 
can’t produce sputum, which is often the case for children and 
very sick persons, a sputum induction can be performed. In this 
instance, the patient is either placed inside a special chamber or 
a hood is placed over the patient’s head, and nebulized saline is 
introduced, causing the patient to cough up sputum.
In children or in presumptive patients having difficulty expec-
torating, specimens can also be obtained by the use of a broncho-
scope, yielding a bronchial wash, bronchial alveolar lavage, or 
biopsy.177 Bronchoscopy can assist in specifically sampling the 
affected area of the lung identified by x-ray. Alternatively, gastric 
lavage is used in patients who are not able to expectorate spu-
tum and, hence, swallow it. Gastric lavage specimens need to be 
processed within 4 hours after collection.178 Gastric lavage had 
higher positivity rates compared to induced sputum for TB diag-
nosis in children and adults.177,179 Data on the isolation of MTBC 
and especially NTM from gastric lavage are scarce.179 Recently, 
examination of stool by GeneXpert MTB/RIF (Cepheid, U.S.A) 
yielded good results and was superior compared to gastric lavage 
in individuals unable to produce sputum.180 This application has 
however not yet been recommended by WHO.
For extrapulmonary disease, biopsies, or body fluids can be 
used for diagnosis. Biopsy specimens can be obtained from any 
site suspected of being infected with mycobacteria. Biopsies of an 
organ can be sampled either by ultrasound guidance or through 
general surgery. Skin lesions can be sampled by punch biopsy, 
scraping the margin of the lesion, or swabbing the ulcerated 
region. Drying of swabs should be avoided. It is rarely productive 
to collect samples from the necrotic center of the lesions. Body 
fluids can be obtained through aseptic fine needle aspiration. 
Urine samples are rarely positive for growth of mycobacteria. If 
indicated, early morning midstream urine should be collected. 
For the LF-LAM assay, any urine sample may do. Blood is not 
commonly used for detection of mycobacteria except for dissem-
inated disease, especially in AIDS patients with low CD4 counts. 
Blood can be inoculated directly into special blood culture 
bottles of some of the automated mycobacterial culture systems.
Specimen Storage and Transport
Although mycobacteria can be recovered several days after 
sample collection, non-delayed processing will increase chances 
of successful isolation. Long delays in processing the sample 
increase the risk of overgrowth by microorganisms from the 
common mircroflora or environmental contamination. This risk 
can be reduced by ensuring refrigerated storage and transport 
(2–8°C), or in case of expected long delays from remote places 
(>7 days) and/or in the absence of an ensured cold-chain, trans-
port medium can be added. To this end, a commercial medium 
like OMNIgene.SPUTUM (DNA Genotek, Canada) or the 
noncommercial cetylpyridinium chloride (CPC) can be added, 
allowing storage and transport at ambient temperature for up to 
8 days or 28 days, respectively, prior to culture. Both reagents 
are also suited to conduct subsequent molecular analysis.181 If 
only molecular analysis are to be done, addition of ethanol (final 
concentration ≥50%) allows for long-term storage (years) and 
shipping at ambient temperature.181
Isolation of Mycobacteria from 
Clinical Specimens (Culture) 
Specimen Processing
Sputa and other specimens collected from the respiratory tract 
are “contaminated” with normal microflora. In addition, spu-
tum is a viscous nonhomogenous specimen. Hence the need to 
process these specimens with a mucolytic agent and a decon-
taminating agent prior to inoculation on culture medium. If not, 
the normal flora will overgrow the more slowly growing species 
of mycobacteria, making their isolation from clinical samples 
impossible.
Several mucolytic and bactericidal/fungicidal reagents are 
used for this purpose.178 The most commonly used are 4% NaOH 
or equal quantities of 4% NaOH solution and sodium citrate 
plus N-acetyl L-cysteine (NALC) solution. The 4% NaOH helps 
in liquefying the specimen as well as killing the normal flora 
of bacteria/fungi. NALC at concentrations of 0.5–2.0%, when 
combined with NaOH, facilitates decontamination by further 
digesting mucopurulent specimens, which allows the NaOH 
to penetrate; sodium citrate aids in the liquification by binding 
heavy metals, thus stabilizing NALC and allowing it to work 
properly. NALC can be used with reduced concentrations of 
NaOH (final concentration of 1% in sputum). For isolation of 
mycobacteria from specimens that are likely contaminated with 
Gram-negative organisms such as Pseudomonas aeruginosa, as 
observed in patients of cystic fibrosis and bronchiectasis, a com-
bination of Nalc-NaOH processing with 5% oxalic acid treatment 
may be more successful.178
The optimal volume of sputum to be processed is 5–10 mL. An 
equal volume of the digesting/decontaminating solution is added 
to the specimen, vortexed, and allowed to stand for 15–20 min-
utes at room temperature. Then, the alkali are either neutralized 
by adding an equal volume of phosphate buffered saline (PBS; 
pH 6.8, 0.067 M) or HCl buffer (1N) till neutral pH as indicated 
by the phenol red indicator, or “washed” by adding an excess 
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(usually till 45 mL total volume) of PBS buffer.178 PBS lowers the 
specific gravity of the specimen and gently neutralizes the speci-
men. The amount of NaOH used, the time allowed for decon-
tamination, and the addition of neutralizing or washing buffer to 
the digested/decontaminated specimen are critical because both 
the common microflora and mycobacteria are affected by the 
exposure to the high pH of sodium hydroxide.
The specimen is then centrifuged at 3,000 × g for 15–20 min-
utes to concentrate the bacilli at the bottom.182 The obtained sedi-
ment can be used to inoculate appropriate culture media, and—in 
case not yet done directly from the nonprocessed specimen—to 
prepare a smear for microscopic examination, or to perform a 
DNA extraction and subsequent molecular analysis.
Urine and other large volume samples should be concentrated 
(15 minutes at 3,000 × g), and nonsterile biopsies minced (sterile 
mortar and pestle) prior to processing. Specimens aseptically 
collected from normally sterile body sites do not need to be pro-
cessed before inoculation into the appropriate media.
Smear Preparation
Smears can be prepared directly from clinical specimens (direct) 
or from the sediment of processed specimens in case culture is 
done as well (indirect).
Staining and Reading of Smears
Since the detection of TB bacilli by Robert Koch, the most com-
monly used dye for staining mycobacteria is basic fuchsine. This 
dye can stain all microorganisms, but only few will retain the dye 
in the cell wall after discoloration with an acid-alcohol solution. 
The composition of the mycobacterial cell wall (mycolic acids) 
of these organisms renders them resistant to discoloration of the 
primary dye, hence the term “acid-fastness.”
The classic method, the Ziehl-Neelsen stain, uses carbol-
fuchsin (0.3%) as the primary dye. In this method, the stain is 
heated until steam arises (three times at intervals of 3–5 minutes) 
to allow optimal penetration of the cell wall. The modified or 
cold Kinyoun stain also uses carbolfuchsin as the primary dye 
but without heating and a contact time of 20–25 minutes. In both 
methods, acid-fast organisms will appear red against the back-
ground stain, which is usually methylene blue. Reading of the 
slides requires objective 100× and the use immersion oil.
Alternatively, fluorescent stains are used that consist of the 
fluorochrome stain auramine, alone or in combination with 
another fluorochrome, rhodamine. These stained smears must 
be read using a fluorescent microscope, where mycobacteria will 
fluoresce a bright yellow to orange. Fluorescence microscopy 
allows reading at a lower magnification (objective 25× or 40×), 
speeding up analysis. However, care must be taken to distinguish 
fluorescing artifacts from true organisms. The introduction of 
LED-based microscopes has enabled the roll out of fluorescence 
microscopy, even to remote places. In 2011, the WHO recom-
mended that conventional fluorescence microscopy be replaced 
by LED microscopy, and that LED microscopy be phased in as 
an alternative for conventional Ziehl-Neelsen light microscopy.183
A minimum of 5,000–10,000 bacilli per mL specimen is 
needed to be observable in microscopy.
Isolation of Mycobacteria by Culture
For an optimal diagnosis of mycobacterial infection, their isola-
tion from clinical specimens is considered as a gold standard. 
Digested, decontaminated, and concentrated specimen is inocu-
lated on culture medium and incubated at 30°C and/or 37°C for 
6–8 weeks to allow growth of mycobacteria. As a rule, media 
inoculated with specimens obtained from skin lesions should 
always be incubated at the regular 37 ± 1°C as well as at the 
lower 30 ± 1°C temperature. Once growth of AFB shows up and 
is confirmed, it is reported as positive. Traditionally one or more 
pieces of a solid medium or one solid and one liquid medium are 
inoculated.
Solid media used for mycobacterial culture can be divided 
into two main categories: egg-based and agar-based media. The 
egg-based media consist of (part of the) eggs, salts, potato flour, 
amino acids, glycerol, and malachite green as an inhibitor of 
bacterial growth from the common microflora persisting prior 
specimen processing. The media are solidified by heating the 
mixture to a temperature of 85°C for approximately 45 minutes 
in a process called inspissation. This process also sterilizes the 
medium. The most common form of egg-based medium used 
in the United States and many other countries is Löwenstein-
Jensen (LJ) medium. Modified egg-based media may be more 
suited for the isolation of specific species. For example, M. bovis 
(BCG) grows better on medium without glycerol and supple-
mented with pyruvate (Coletsos or Stonebrink medium), while 
M. haemophilum needs addition of ferric-ammonium citrate 
for its growth. Agar-based media commonly employed are 
Middlebrook 7H10 and 7H11, both containing defined salt con-
centrations, growth factors such as oleic acid, albumin, catalase, 
glycerol, and a low concentration of malachite green. Medium 
7H11 differs from 7H10 by the addition of pancreatic digest of 
casein to facilitate the growth of fastidious MTBC cultures.184 
Recently a new selective agar-based medium has been developed 
(“rapid growing mycobacteria” RGM), which enabled sensitive 
(98%) detection of NTM from CF patient samples.185 Prolonged 
incubation up to 26 days further increased growth of MAC, with 
higher recovery compared to the classical medium for isolation 
of mycobacteria.186,187
Solid media can be prepared in house or purchased as ready-
to-use from commercial companies. They may be supplemented 
with antibiotic mixtures to further reduce culture contamination 
rates. As, the optimal growth temperature for most NTM ranges 
between 28°C and 37°C, it is important to incubate at least one 
tube at 37°C and one at 30°C, especially in case of biopsies or 
pus from skin lesions.
In resource-poor settings, specimens can be cultured using 
only LJ medium, but for optimal isolation of mycobacteria 
from clinical specimens, both liquid and solid media should be 
employed to decrease the time to positivity and to increase the 
probability of a positive result (>10%).188 The number of posi-
tive cultures for liquid is significantly higher than for any solid 
medium. Several automated systems using liquid medium for 
isolation of mycobacteria have been developed and are now 
used routinely in many laboratories, with the BACTEC 460 (BD 
Diagnostic Systems, U.S.) being the first introduced in the 1980s. 
This semiautomated system utilized a modified Middlebrook 
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7H9 broth containing a radiolabeled substrate that would be 
hydrolyzed by microorganisms growing in the medium, releas-
ing radiolabeled carbon dioxide that was measured as an indica-
tor of growth. The BACTEC 460 system has been discontinued 
due to concerns of radioactivity and its disposal and has been 
replaced by the nonradiometric BACTEC MGIT 960 system 
(BD Diagnostic Systems, Sparks, MD). This system builds on the 
principle of oxygen consumption by growing organisms. Oxygen 
present in the medium quenches the fluorescent indicator embed-
ded in silicone at the bottom of the tube. When the oxygen is 
consumed by growing bacilli, the tubes will begin to fluoresce 
in the presence of UV light. Automated reading each hour, will 
flag these tubes as positive. The instrument provides the time 
to positivity and a growth-unit value (GU). Prior to specimen 
inoculation, a growth supplement including an antibiotic mixture 
(PANTA) must be added. MGIT 960 can be used for all types 
of specimens except for blood. Blood must be inoculated into a 
different type of bottle, the MYCO/F Lytic F, and incubated in a 
different instrument, the BACTEC 9240.
Bacterial contamination, which survives decontamination and 
grows in the presence of added antibiotics, can lead to a false-
positive result. Unlike solid medium, liquid medium does not 
allow for the observation of colony characteristics, colony counts 
or mixed cultures. Any positive culture must therefore be con-
firmed by acid-fast staining, and, if possible, by purity check on 
a blood agar.
Scores of publications have verified MGIT 960 superior per-
formance over solid media.
A couple of other commercial automated liquid systems 
have been introduced, such as VersaTREK Myco System (Trek 
Diagnostic Systems, U.S.A) and BacT/Alert (Biomérieux, 
France), but these systems are less commonly used.
Identification of Mycobacteria
It is imperative that MTBC can be immediately distinguished 
from NTM.
Upon isolation, initial mycobacterial species identification may 
rely on the observed growth rate (rapid versus slow), pigmenta-
tion, and colony appearance, the latter mainly observable from 
solid medium. They are described as either buff (white- to cream-
colored colony) or a chromogen (yellow to orange pigmentation). 
The chromogens are classified as scoto- or photochromogenic, 
with scotochromogens being pigmented regardless of growing in 
the light or dark, whereas photochromogens will only develop pig-
ment if exposed to light.183 Most mycobacteria can be speciated by 
their biochemical profile,183 which can be very tedious, requiring 
up to several weeks, and may not always allow for reliable (sub)
species differentiation. Susceptibility to paranitrobenzoic acid 
(PNB; 500 µg/mL) has for long been a marker to differentiate 
MTBC from PNB-resistant NTM.189 In most laboratories, how-
ever, molecular assays have displaced biochemical tests.
To rapidly differentiate MTBC from NTM growth, a lateral 
flow immunochromatographic assay detecting the presence of 
the MTBc-associated MPT 64 antigen has been developed. Three 
commercial tests are available: Capilia TB NEO (Tauns, Japan), 
BD MGIT™ TBc ID test (Becton Dickinson, U.S.), and SD Bioline 
TB Ag MPT64 Rapid (Standard Diagnostics, South  Korea). 
In 15 minutes, the tests differentiate MTBC species from NTM 
in a positive culture. In a multicenter study, all three tests showed 
100% sensitivity for detection of MTB from MGIT on the day of 
positivity. While the BD assay is not indicated for use with solid 
media cultures, the sensitivity of Capilia and SD Bioline assays 
was also 100% when applied on isolates grown on LJ cultures.190 
The SD Bioline assay may yield a weak false-positive result with 
M. gastri.190 In a comparative study in Uganda, the SD Bioline 
assay performed equally well as the PNB assay.191 Of note, not 
all MTBC lineages may be detected with a similar sensitivity, as 
evidenced by false-negative reactions for M. africanum in Benin 
and the Gambia.192,193
In case no MTBC is detected by an MPT64-based assay or 
an MTBC-specific molecular assay, most laboratories rely now 
on molecular testing for further NTM speciation. In house PCR- 
and sequencing-based identification of conserved genes is the 
reference method for the identification of mycobacteria.5 This 
technology commonly targets a number of housekeeping genes, 
such as the ones encoding the 16S rRNA (rrs), the 65-kDa heat 
shock protein (hsp65), the RNA polymerase β-subunit (rpoB), 
bus is mostly restricted to reference laboratories. The vast major-
ity of clinical laboratories will make use of commercially avail-
able assays.5 While these can reliably differentiate MTBC from 
other mycobacterial species with very high sensitivity and speci-
ficity, they can identify only a limited number of NTM species. A 
comprehensive overview of various (molecular) assays for NTM 
species identification, discussing advantages, and shortcomings 
is provided by Misch and colleagues.27 Some examples are dis-
cussed next.
The FDA-approved AccuProbe test (Gen-Probe, U.S.A) has 
single-stranded DNA probes that hybridize with ribosomal RNA 
from several mycobacterial species. It has probes specific for 
MTBC, M. avium complex, M. kansasii, and M. gordonae. The 
test can be used directly from positive cultures, within clinically 
relevant time frames (24–48 hours), with a sensitivity and speci-
ficity comparable to the lateral flow assay, yet requiring more 
complex manipulations.
Numerous assays based on the reversed hybridization line probe 
technology have been developed for the identification of myco-
bacteria: the InnoLiPA Mycobacteria (Innogenetics, Belgium) 
identifying 13 NTM species, and various GenoType assays from 
Hain Lifescience (Germany). The GenoType Mycobacterium CM 
and GenoType Cmdirect both differentiate >20 common NTM 
species and MTBc, with the former requiring a positive culture, 
while the latter can also be used directly on decontaminated 
sputum. The GenoType NTM-DR allows for the same species 
identification as “CM,” but in addition detects resistance muta-
tions associated with clarithromycin and amikacin. For further 
identification of 19 less common NTM species, the GenoType 
Mycobacterium AS can be used on positive cultures.
In addition, molecular tests used for direct detection of MTBC 
in clinical specimens can also be used for identification of MTBC 
in grown cultures.
The cumbersome analysis of mycolic acid profiles using high 
performance (or pressure) liquid chromatography (HPLC), is 
nowadays rarely used in routine practice. The commercialized 
Sherlock Midi system (Midi Labs, Newark, DE), contains a 
database to which the profile of the unknown organism can be 
matched to speciate the isolate.
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In clinical practice, matrix-assisted laser desorption/ioniza-
tion time-of-flight (MALDI-TOF) mass spectrometry has shown 
value in replacing the more costly and time-consuming 16S 
rRNA gene PCR and sequencing-based approach as the pri-
mary method for identification of microorganisms.194 In a recent 
multicenter study, two commercial databases (Bruker Biotyper 
with Mycobacterial Library v5.0.0 and bioMérieux VITEK 
MS with v3.0 database) showed comparable performance, with 
92% and 95% of NTM strains identified at least to the complex/
group level, and 62% and 57% to the highest taxonomic level.195 
Differentiation between members of M. abscessus, M. fortuitum, 
M. mucogenicum, M. avium, and M. terrae complexes/groups 
was problematic for both systems, as was identification of M. che-
lonae for the Bruker system.195 Similarly, a seeded-culture study 
that incorporated clinically prevalent respiratory microbiota, 
achieved 99% correct identification of mycobacteria, indicating 
that residual patient microbiota in a positive liquid culture was 
reduced by the Vitek MS.196 In another study, the MAC subtyper 
module using the MALDI Biotyper algorithm, allowed for cor-
rect identification of 100% of the M. intracellulare and 82% of 
the M. chimaera, two closely related species.197 Forero-Morales 
and colleagues have described a novel mycobacterial inactivation 
and protein extraction protocol (MIPE), which provides reliable 
MALDI-TOF results from solid and liquid media, while ensuring 
laboratory safety.198 Finally, MALDI-TOF MS is intended for the 
identification of pure cultures; mixed Mycobacterium cultures 
present a challenge, as both species may not be distinguishable, 
especially in case of closely related taxa.199
Finally, the next-generation sequencing based Deeplex 
Myc-TB assay (Genoscreen, Lille, France), can detect 156 myco-
bacterial species either directly from smear-positive clinical 
specimens or from positive cultures, using nucleotide identity at 
the hsp65 gene.200
Direct Testing of Specimens for Mycobacterium 
Tuberculosis Using Molecular Methods
Molecular diagnostics can be used to test directly on clinical 
specimens. Several commercial assays for detection of MTBC 
are being used since the 1990s (Table 33.2), such as the isother-
mal MTD amplification test by Gen-Probe (San Diego, U.S.A), 
the ProbeTec ET Mycobacterium tuberculosis complex Direct 
Test (DTB) (Becton-Dickinson), or the COBAS Taq-Man MTB 
Test (Roche Molecular Systems, Indianapolis, U.S.A). These 
assays were approved for AFB smear-positive respiratory speci-
mens, yet require large instruments, are expensive or can be 
cumbersome.
Among the most common newer commercial molecular 
tests are the GenoType MTBC (Hain Lifesciences, GmbH, 
Nehren, Germany) and the less commonly used INNO-LiPA 
Mycobacteria (LiPA Innogenetics, Ghent, Belgium). These tests 
detect MTBc in a clinical specimen. The sensitivity and speci-
ficity are good in smear-positive sputum specimens but low in 
smear-negative specimens.
The most recently introduced is the Gene Xpert MTB/RIF 
(Cepheid, California, U.S.A) automated test. It is the most sim-
ple and rapid test with results available within 2-hours’ time. 
Specimen is mixed with a reagent in a measured quantity and 
is placed in the instrument. All the necessary molecular proce-
dures are automatically carried out inside the instrument, and 
results for the presence or absence of the MTBc and presence of 
rifampicin resistance is displayed within two hours. Sensitivity 
and specificity for smear-positive is very high, but for smear-
negative specimens is rather low. This system has been tried in 
the peripheral sites with encouraging results.40 Detection from 
smear-negative and culture-positive specimens needs improve-
ment while detection of rifampicin resistance at a low level may 
be a concern.41
Other less commonly used commercial CE-labeled real-time 
PCR systems are available:
• The artus Mycobacterium tuberculosis RG PCR (artus 
MTB) kit (QIAGEN, Germany) has also been approved 
by the FDA and detects MTBc and/or MAC.
TABLE 33.2
Overview of FDA-Approved Nucleic-Acid Amplification 





Xpert MTB/RIF Assay Cepheid
BDProbetec ET Mycobacterium 















Rapid Diagnostic System for 
Mycobacterium tuberculosis
Gen-Probe, Inc.






Accuprobe Mycobacterium avium 
complex culture
Gen-Probe, Inc.
Accuprobe Mycobacterium kansasii 
Identification Test
Gen-Probe, Inc.
SNAP Mycobacterium avium complex Syngene, Inc.
Accuprobe Mycobacterium 
intracellulare Culture Identification 
Test
Gen-Probe, Inc.
Accuprobe Mycobacterium gordonae 
culture identification Test
Gen-Probe, Inc.
Rapid Diagnostic System for 
Mycobacterium gordonae
Gen-Probe, Inc.
Rapid Diagnostic System for 
Mycobacteria
Gen-Probe, Inc.
Rapid Identification Test for 
Mycobacterium avium
Gen-Probe, Inc.




acid-based-tests (update September 8, 2020).
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• The Geno-Sen’s MTC/MOTT Real-Time PCR (Corbett 
Research, Australia) detects the genus Mycobacterium 
and MTBC.
• The Abbott RealTime MTB (Abbott Diagnostics, 
U.S.A) detects MTBC, while the variant Abbott 
RealTime MTB RIF/INH allows for simultaneous 
detection of resistance to rifampicin and/or isoniazid.
• The Speed-oligo Direct Mycobacterium tuberculosis 
assay (Vircell, Spain) includes an automated or manual 
post-PCR strip hybridization (dipstick format).
• The Truenat MTB Plus (MolBio, India) allows for 
detection of MTBC, while the Truenat MTB-RIF Dx 
subsequently detects rifampicin resistance in M. tuber-
culosis in Truenat MTB/MTB Plus positive specimens.
More sophisticated micro-array or lab-on chip-based 
CE-approved systems comprise:
• The CapitalBio Mycobacteria Real-Time PCR 
Detection Kit (CapitalBio Corporation, China) detects 
and differentiates MTBC from NTM, while the 
CapitalBio M. tuberculosis Drug Resistance Array Kit 
in addition detects 14 of the most frequent mutations 
associated with resistance to isoniazid and rifampicin.
• The VereMTB™ Detection Kit (Veredus Laboratories, 
Singapore) simultaneously detects MTBC, resistance 
to rifampicin and isoniazid, as well as 14 NTM species.




Details of drugs effective against clinically important mycobacteria 
and procedures for drug-susceptibility testing (DST) can be found 
in the Clinical Laboratory Standard Institutes (CLSI) guidelines.201
Susceptibility testing of MTBc isolates is advisable even in 
newly diagnosed infections, as an individual may have been 
infected with a resistant strain (primary resistance),202 and drug 
resistance rates vary widely across global regions and settings. The 
WHO therefore recommends “universal DST,” i.e., the search and 
identification of RR-TB among new TB patients, wherever this is 
logistically feasible.203 Universal DST in all presumptive TB cases 
in the GeneXpert-based algorithm in South Africa resulted in a 
higher overall proportion of MDR-TB cases being diagnosed.164
Regarding susceptibility testing of NTM, the U.S. CLSI pro-
vides clear guidance on when and how to test and how to interpret 
minimal inhibitory concentrations (MICs),201 while the British 
Thoracic Society recommends to follow CLSI, admitting that evi-
dence is poor and DST should only be carried out on isolates where 
there is clinical suspicion of disease.29 In the absence of clear in 
vitro/in vivo associations and clear-cut test concentrations for most 
NTM and drugs, the British guidelines distilled some evidence 
statements that could guide patient management (Table 33.3).
Overall, there are two major approaches for testing drug resis-
tance, using culture-based or phenotypic and molecular-based or 
genotypic methods, with NTM-DST being mostly limited to phe-
notypic DST, with preference for MIC determination and reporting.
Phenotypic Susceptibility Testing
Culture-based or phenotypic DST can be performed on solid or 
in liquid medium, the latter having the preference for MTBC in 
terms of speed, and for NTM in terms of reliability. TB-DST 
should always be carried out in a confined laboratory following 
at least the safety precautions recommended by WHO.204
Classically, TB drug susceptibility testing is performed on 
the same solid media as used for primary isolation, such as LJ 
or Middlebrook 7H10 and 7H11 agar medium. The proportion 
method is the most applied, establishing the proportion of bacilli 
growing on culture-containing medium as compared to drug-
free slants, considering an isolate as clinically resistant if >1% of 
the bacterial population resists the drug. To this end, an appro-
priate bacterial suspension (e.g., 10−3 dilution MacFarland #1) of 
the isolated culture is inoculated on the drug-containing slants, 
while a 1:100 dilution of the same suspension is inoculated on ad 
drug-free control. Solid media for DST can be obtained commer-
cially or prepared in house. The drugs are added to the medium 
prior to coagulation. With exception of pyrazinamide (PZA) all 
TB drugs can be tested on solid medium, with clearly defined 
critical concentrations, specific for the drug and medium used.205 
Of note, LJ medium should not be used for bedaquiline suscepti-
bility testing, because of its high protein-binding capacity. Solid 
medium DST, while being reliable, requires at least 3–4 weeks of 
incubation, with preferably a second reading at 6 weeks,205 which 
is not in keeping with current U.S. Centers for Disease Control 
recommendations.202
TABLE 33.3
Evidence-Based Impact of Drug Resistance on NTM Treatment Outcome
Species Disease Presentation In Vitro Resistancea to Impact Evidence Levelb
MAC Not specified Macrolides & amikacin Treatment failure 2++
M. kansasii Not specified Rifampicin Treatment failure 2++
M. abscessus Pulmonary Macrolides Treatment failure 2++
M. abscessus Extrapulmonary Cefoxitin, amikacin and 
co-trimoxazole
Treatment failure 2++
 Source: Adapted from Ref. [28].
a determined by broth dilution.
b 2++ = High-quality. Systematic reviews of case– control or cohort studies, or high quality case–control or cohort 
studies with a very low risk of confounding, bias or chance, and a high probability that the relationship is causal.
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The use of liquid medium for detection and drug susceptibility 
testing has been recommended by the U.S. Centers for Disease 
Control and WHO,202,204 MGIT 960 is the most widespread used 
liquid culture system for susceptibility testing of isolated MTBC 
against first- and second-line drugs, as well as new drugs like 
bedaquiline208 and delamanid.209,210 The system also relies on 
the proportion method principle, and results can be reported as 
early as 5–7 days after primary isolation. Details of the MGIT 
DST procedure are covered in the MGIT Manual published by 
FIND.211 First-line and some of the second-line drugs are avail-
able in ready-to-use lyophilized form, while others need to be 
purchased and dissolved/diluted in house. Although recom-
mended by WHO and CDC, MGIT960 testing risks to miss some 
cases of rifampicin resistance.212,213
PZA testing requires a low pH (pH 5.0) which can be achieved 
using adapted MGIT medium (BACTEC™ MGIT™ 960 PZA 
Kit), the only recommended phenotypic assay, despite previous 
association with a high rate of false-resistance results.201,207 Several 
studies have shown good agreement of MGIT-PZA testing with 
pncA sequencing, if done meticulously; careful inoculum prepara-
tion is essential for correctly performing PZA testing reliably.214
Regarding NTM susceptibility testing, a variety of methods 
have been proposed, including broth dilution tests, the E-test, 
and proportional- and absolute-concentration methods.42 E-tests 
suffer from high intra- and interlaboratory variability, and the 
proportional method on solid media or in MGIT has its break-
points not yet defined for NTM. Hence the preference for the 
broth microdilution method.201
Molecular-Based Drug-susceptibility Testing
In the last decade, several genotypic DST procedures have been 
introduced, detecting mutations in one or more specific genes 
associated with resistance to (a) particular (class of) drugs. 
Genotypic testing is significantly faster than phenotypic test-
ing. Among the first-line drugs, molecular testing overall has 
an excellent sensitivity for rifampicin and a good sensitivity for 
isoniazid, while both having excellent specificity. Sensitivity and 
specificity for ethambutol and PZA are debatable. Regarding 
second-line drugs, both for injectables and fluoroquinolones a 
relatively high sensitivity is observed. Details of the likelihood of 
association with drug resistance can be found on the Relational 
Sequencing TB Knowledgebase (ReSeqTB) platform (https://
platform.reseqtb.org/).215
The FDA-approved GeneXpert MTB/RIF is the most widely 
used assay, with a pooled sensitivity and specificity of 96.8% and 
98.4%, respectively, to correctly identify rifampicin-resistance in 
clinical specimens.216 False-resistant results have been associated 
with a low bacillary load,217,218,219 or the presence of synonymous 
mutations not associated with resistance.220 Therefore, it is rec-
ommended to repeat testing in case of a low pretest probability 
for rifampicin resistance or a very low bacillary load. The new 
version Xpert Ultra may be more specific as it includes melting 
temperatures to identify the mutation type.221 Further roll out of 
this version will provide data on its performance as an initial 
diagnostic test in field settings.
Results for the clinical evaluation of the chip-based real-time 
micro-PCR Truenat MTB-RIF Dx (MolBio, India) are expected 
by 2020.
While not being FDA approved, the WHO has endorsed the 
GenoType MTBDRplus (Hain Lifesciences, Germany) and the 
Genoscholar NTM-MDR TB (Nipro, Japan) line probe assays for 
detection of resistance to rifampicin and isoniazid in cultures and 
smear-positive samples.222 Likewise, the GenoType MTBDRsl 
(Hain Lifesciences, Germany) can detect resistance to fluoroqui-
nolones and second-line injectables.223 The only assay for rapid 
detection of PZA resistance (Genoscholar PZA-TB II) has not 
been endorsed yet.224
Finally, next-generation sequencing-based Deeplex Myc-TB 
assay (Genoscreen, Lille, France) can predict resistance to 
13 anti-TB drugs/drug classes, directly from smear-positive 
sputum or from culture isolates.225 This assay has not yet been 
CE or FDA approved. Likewise, whole genome sequencing 
can predict TB drug resistance with a good sensitivity and 
specificity for most drugs,226 albeit with yet unclear genotypic-
phenotypic associations for new drugs like bedaquiline and 
delamanid.227,228
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 39. Dakić, I. et al. Pulmonary isolation and clinical relevance of 
nontuberculous mycobacteria during nationwide survey in 
Serbia, 2010–2015. PLOS One 13, e0207751 (2018). 
 40. Schiff, H.F. et al. Clinical relevance of non-tuberculous myco-
bacteria isolated from respiratory specimens: seven year expe-
rience in a UK hospital. Sci Rep 9, (2019).
 41. Perez, J.J.B. et al. Clinical significance of environmental 
mycobacteria isolated from respiratory specimens of patients 
with and without silicosis. Arch Bronconeumol 52, 145–150 
(2016).
 42. Wassilew, N., Hoffmann, H., Andrejak, C. & Lange, C. 
Pulmonary disease caused by Non-Tuberculous Mycobacteria. 
Respiration 91, 386–402 (2016).
 43. Adjemian, J. et al. Epidemiology of nontuberculous myco-
bacterial lung disease and tuberculosis, Hawaii, USA. Emerg 
Infect Dis 23, 439–447 (2017). 
 44. Garima, K. et al. Are we overlooking infections owing to non-
tuberculous mycobacteria during routine conventional labora-
tory investigations? Int J Mycobacteriol 1, 207–211 (2012).
 45. Varghese, B. et al. The first Saudi Arabian national inventory 
study revealed the upcoming challenges of highly diverse non-
tuberculous mycobacterial diseases. PLOS Negl Trop Dis 12, 
(2018).
 46. Tortoli, E. Epidemiology of cervico-facial pediatric lymph-
adenitis as a result of nontuberculous mycobacteria. Int 
J Mycobacteriol 1, 165–169 (2012).
 47. Heraud, D., Carr, R.D., McKee, J. & Dehority, W. 
Nontuberculous mycobacterial adenitis outside of the head 
and neck region in children: a case report and systematic 
review of the literature. Int J Mycobacteriol 5, 351–353 (2016).
BK-TandF-GREEN_9780367567637-200126-Chp33.indd   457 27/02/21   3:19 PM
458 Practical Handbook of Microbiology
 48. Shih, D.C. et al. Extrapulmonary nontuberculous mycobac-
terial disease surveillance–Oregon, 2014-2016. Morb Mortal 
Wkly Rep 67, 854–857 (2018).
 49. Kaestli, M. et al. Opportunistic pathogens and large microbial 
diversity detected in source-to-distribution drinking water of 
three remote communities in Northern Australia. PLOS Negl 
Trop Dis 13, e0007672 (2019).
 50. Marini, E. et al. Efficacy of carvacrol against resistant rapidly 
growing mycobacteria in the planktonic and biofilm growth 
mode. PLOS One 14, (2019). 
 51. Cox, K.E. & Melander, C. Anti-biofilm activity of quin-
azoline derivatives against Mycobacterium smegmatis. 
MedChemComm 10, 1177–1179 (2019). 
 52. Wargo, M.J. Is the potable water system an advantageous pre-
infection niche for bacteria colonizing the cystic fibrosis lung? 
mBio 10, (2019).
 53. Waak, M.B., LaPara, T.M., Halle, C. & Hozalski, R.M. 
Nontuberculous Mycobacteria in two drinking water distribu-
tion systems and the role of residual disinfection. Environ Sci 
Tech 53, 8563–8573 (2019).
 54. Cusumano, L.R. et al. Rapidly growing Mycobacterium infec-
tions after cosmetic surgery in medical tourists: the Bronx 
experience and a review of the literature. Int J Infect Dis 63, 
1–6 (2017).
 55. Avanzi, A., Bierbauer, K., Vales-Kennedy, G. & Covino, J. 
Nontuberculous mycobacteria infection risk in medical tour-
ism. JAAPA 31, 45–47 (2018).
 56. Torres-Coy, J.A., Rodriguez-Castillo, B.A., Perez-Alfonzo, 
R. & de Waard, J.H. Source investigation of two outbreaks 
of skin and soft tissue infection by Mycobacterium absces-
sus subsp abscessus in Venezuela. Epidemiol Infect 144, 
1117–1120 (2016).
 57. Yacisin, K. et al. Outbreak of non-tuberculous mycobacteria 
skin or soft tissue infections associated with handling fish - 
New York City, 2013-2014. Epidemiol Infect 145, 2269–2279 
(2017).
 58. Kennedy, B.S. et al. Outbreak of Mycobacterium chelo-
nae infection associated with Tattoo Ink. N Eng J Med 367, 
1020–1024 (2012). 
 59. Henkle, E., Hedberg, K., Schafer, S.D. & Winthrop, K.L. 
Surveillance of extrapulmonary nontuberculous mycobacteria 
infections, Oregon, USA, 2007–2012. Emerg Infect Dis 23, 
1627–1630 (2017). 
 60. Chavarro-Portillo, B., Soto, C.Y. & Guerrero, M.I. 
Mycobacterium leprae’s evolution and environmental adapta-
tion. Acta Trop 197, 105041 (2019). 
 61. Logas, C.M. & Holloway, K.B. Cutaneous leprosy in Central 
Florida man with significant armadillo exposure. BMJ Case 
Rep 12, (2019), doi: 10.1136/bcr-2019-229287. 
 62. World Health Organization. WHO Guidelines for the diag-
nosis, treatment and prevention of leprosy. World Health 
Organization Document, ISBN: 978 92 9022 638 3 (2018).
 63. World Health Organization. Treatment of Mycobacterium 
ulcerans disease (Buruli ulcer). World Health Organization 
Document, WHO/HTM/NTD/IDM/2012.1, 1–66 (2012).
 64. Johnson, P.D.R. et al. Mycobacterium ulcerans in mosqui-
toes captured during outbreak of Buruli ulcer, southeastern 
Australia. Emerg Infect Dis 13, 1653–1660 (2007).
 65. Lavender, C.J. et al. Risk of Buruli ulcer and detection of 
Mycobacterium ulcerans in mosquitoes in southeastern 
Australia. PLOS Negl Trop Dis 5, e1305 (2011).
 66. Singh, A., McBride, J.H.W., Govan, B. & Pearson, M. Survey 
of local fauna from endemic areas of northern Queensland, 
Australia for the presence of Mycobacterium ulcerans. Int J 
Mycobacteriol 8, 48–52 (2019).
 67. Portaels, F. et al. First cultivation and characterization of 
Mycobacterium ulcerans from the Environment. PLOS Neg 
Trop Dis 2, (2008).
 68. van Ingen, J., Turenne, C.Y., Tortoli, E., Wallace, R.J., Jr. & 
Brown-Elliott, B.A. A definition of the Mycobacterium avium 
complex for taxonomical and clinical purposes, a review. Int J 
Syst Evol Microbiol 68, 3666–3677 (2018).
 69. Tortoli, E. et al. The new phylogeny of the genus 
Mycobacterium: The old and the news. Infect Genet Evol 56, 
19–25 (2017).
 70. Kim, S.Y. et al. Distribution and clinical significance of 
Mycobacterium avium complex species isolated from respi-
ratory specimens. Diagn Microbiol Infect Dis 88, 125–137 
(2017).
 71. Honda, J.R., Virdi, R. & Chan, E.D. Global environmental 
nontuberculous mycobacteria and their contemporaneous 
man-made and natural niches. Front Microbiol 9, (2018).
 72. Hamilton, K.A., Ahmed, W., Toze, S. & Haas, C.N. Human 
health risks for Legionella and Mycobacterium avium com-
plex (MAC) from potable and non-potable uses of roof-
harvested rainwater. Water Res 119, 288–303 (2017).
 73. Horsburgh, C.R. et al. Geographic and seasonal variation in 
Mycobacterium avium bacteremia among North American 
patients with AIDS. A J Med Sci 313, 341–345 (1997).
 74. Benjak, A. et al. Insights from the genome sequence of 
Mycobacterium lepraemurium: massive gene decay and 
reductive evolution. mBio 8, (2017). 
 75. O’Brien, C.R. et al. Feline leprosy due to Mycobacterium lep-
raemurium: Further clinical and molecular characterisation 
of 23 previously reported cases and an additional 42 cases. 
J Feline Med Surgery 19, 737–746 (2017). 
 76. Brown-Elliott, B.A., Nash, K.A. & Wallace, R.J., Jr. 
Antimicrobial susceptibility testing, drug resistance mecha-
nisms, and therapy of infections with nontuberculous myco-
bacteria. Clin Microbiol Rev 25, 545–82 (2012). 
 77. Turenne, C.Y., Wallace, R., Jr. & Behr, M.A. Mycobacterium 
avium in the postgenomic era. Clin Microbiol Rev 20, 205–29 
(2007).
 78. Thorel, M.F., Krichevsky, M. & Levy-Frebault, V.V. 
Numerical taxonomy of mycobactin-dependent mycobacteria, 
emended description of Mycobacterium avium, and descrip-
tion of Mycobacterium avium subsp. avium subsp. nov., 
Mycobacterium avium subsp. paratuberculosis subsp. nov., 
and Mycobacterium avium subsp. silvaticum subsp. nov. Int 
J Syst Bacteriol 40, 254–60 (1990).
 79. Mijs, W. et al. Molecular evidence to support a proposal to 
reserve the designation Mycobacterium avium subsp. avium 
for bird-type isolates and ‘M. avium subsp. hominissuis’ for 
the human/porcine type of M. avium. Int J Syst Evol Microbiol 
52, 1505–18 (2002).
 80. Shin, S.J. et al. Efficient differentiation of Mycobacterium 
avium complex species and subspecies by use of five-target 
multiplex PCR. J Clin Microbiol 48, 4057–62 (2010).
 81. Alvarez, J. et al. Genetic diversity of Mycobacterium avium 
isolates recovered from clinical samples and from the envi-
ronment: molecular characterization for diagnostic purposes. 
J Clin Microbiol 46, 1246–51 (2008).
BK-TandF-GREEN_9780367567637-200126-Chp33.indd   458 27/02/21   3:19 PM
459The Genus Mycobacterium
 82. Feller, M. et al. Mycobacterium avium subspecies paratuber-
culosis and Crohn’s disease: a systematic review and meta-
analysis. Lancet Infect Dis 7, 607–613 (2007).
 83. McNees, A.L., Markesich, D., Zayyani, N.R. & Graham, D.Y. 
Mycobacterium paratuberculosis as a cause of Crohn’s dis-
ease. Expert Rev Gastroenterol Hepatol 9, 1523–34 (2015).
 84. Harris, J.E. & Lammerding, A.M. Crohn’s disease and 
Mycobacterium avium subsp. paratuberculosis: current issues. 
J Food Prot 64, 2103–10 (2001).
 85. Tortoli, E. et al. Genome-based taxonomic revision detects 
a number of synonymous taxa in the genus Mycobacterium. 
Infect Genet Evol 75, 103983 (2019).
 86. Wells, S.J. et al. Evaluation of a rapid fecal PCR test for detec-
tion of Mycobacterium avium subsp. paratuberculosis in dairy 
cattle. Clin Vaccine Immunol 13, 1125–30 (2006).
 87. van Ingen, J. et al. Global outbreak of severe Mycobacterium 
chimaera disease after cardiac surgery: a molecular epidemi-
ological study. Lancet Infect Dis 17, 1033–1041 (2017).
 88. Sax, H. et al. Prolonged outbreak of Mycobacterium chimaera 
infection after open-chest heart surgery. Clin Infect Dis 61, 
67–75 (2015). 
 89. Castejon, M., Menendez, M.C., Comas, I., Vicente, A. 
& Garcia, M.J. Whole-genome sequence analysis of the 
Mycobacterium avium complex and proposal of the transfer 
of Mycobacterium yongonense to Mycobacterium intracellu-
lare subsp. yongonense subsp. nov. Int J Syst Evol Microbiol 
68, 1998–2005 (2018).
 90. Lee, S.Y. et al. Mycobacterium paraintracellulare sp. nov., 
for the genotype INT-1 of Mycobacterium intracellulare. 
Int J Syst Evol Microbiol 66, 3132–41 (2016).
 91. LaBombardi, V.J. & Nord, J.A. Clinical and laboratory 
aspects of Mycobacterium haemophilum infections. Rev Med 
Microbiol 9, 49–54 (1998).
 92. Armstrong, K.L., James, R.W., Dawson, D.J., Francis, P.W. & 
Masters, B. Mycobacterium-haemophilum causing perihilar 
or cervical lymphadenitis in healthy-children. J Pediatr 121, 
202–205 (1992).
 93. Sompolinsky, D., Lagziel, A., Naveh, D. & Yankilevitz, T. 
Mycobacterium haemophilum sp-nov, a new pathogen of 
humans. Int J System Bacteriol 28, 67–75 (1978).
 94. Nookeu, P., Angkasekwinai, N., Foongladda, S. & Phoompoung, 
P. Clinical characteristics and treatment outcomes for patients 
infected with Mycobacterium haemophilum. Emerg Infect Dis 
25, 1648–1652 (2019).
 95. Lindeboom, J.A., Bruijnesteijn van Coppenraet, L.E.S., van 
Soolingen, D., Prins, J.M. & Kuijper, E.J. Clinical manifesta-
tions, diagnosis, and treatment of Mycobacterium haemophi-
lum infections. Clin Microbiol Rev 24, 701–717 (2011).
 96. Maliwan, N. & Zvetina, J.R. Clinical features and follow up of 
302 patients with Mycobacterium kansasii pulmonary infec-
tion: a 50 year experience. Postgrad Med J 81, 530–533 (2005).
 97. Nakamura, T. et al. Mycobacterium kansasii arthritis of the 
foot in a patient with systemic lupus erythematosus. Intern 
Med 40, 1045–1049 (2001).
 98. Moon, S.M. et al. Clinical significance of Mycobacterium 
kansasii isolates from respiratory specimens. PLOS One 10, 
e0139621 (2015).
 99. Shahraki, A.H. et al. Mycobacterium persicum sp. nov., 
a novel species closely related to Mycobacterium kansa-
sii and Mycobacterium gastri. Int J Syst Evol Microbiol 67, 
1766–1770 (2017).
 100. Tagini, F. et al. Phylogenomics reveal that Mycobacterium 
kansasii subtypes are species-level lineages. Description of 
Mycobacterium pseudokansasii sp. nov., Mycobacterium 
innocens sp. nov. and Mycobacterium attenuatum sp. nov. Int 
J Syst Evol Microbiol 69, 1696–1704 (2019).
 101. Hoefsloot, W. et al. Clinical relevance of Mycobacterium mal-
moense isolation in the Netherlands. Eur Respir J 34, 926–931 
(2009).
 102. Petrie, G. et al. Pulmonary disease caused by M-malmoense 
in HIV negative patients: 5-yr follow-up of patients receiving 
standardised treatment. Euro Respir Jl 21, 478–482 (2003).
 103. Lopez-Calleja, A.I., Lezcano, M.A., Samper, S., de Juan, F. 
& Revillo, M.J. Mycobacterium malmoense lymphadenitis 
in Spain: first two cases in immunocompetent patients. Eur J 
Clin Microbiol Infect Dis 23, 567–9 (2004). 
 104. Schroder, K.H. & Juhlin, I. Mycobacterium-malmoense 
sp-nov. Int J System Bacteriol 27, 241–246 (1977). 
 105. Jenkins, P.A. et al. Clarithromycin vs ciprofloxacin as adjuncts 
to rifampicin and ethambutol in treating opportunist myco-
bacterial lung diseases and an assessment of Mycobacterium 
vaccae immunotherapy. Thorax 63, 627–634 (2008).
 106. Andréjak, C. et al. Mycobacterium xenopi pulmonary infec-
tions: a multicentric retrospective study of 136 cases in north-
east France. Thorax 64, 291–296 (2009).
 107. Duan, H. et al. Clinical significance of nontuberculous myco-
bacteria isolated from respiratory specimens in a Chinese 
Tuberculosis Tertiary Care Center. Sci Rep 6, 36299 (2016).
 108. Schwabacher, H. A strain of mycobacterium isolated from 
skin lesions of a cold-blooded animal, Xenopus laevis, and its 
relation to atypical acid-fast bacilli occurring in man. J Hyg 
(Lond) 57, 57–67 (1959).
 109. Diel, R. et al. Microbiological and clinical outcomes of treat-
ing non-Mycobacterium avium complex nontuberculous 
mycobacterial pulmonary disease. A systematic review and 
meta-analysis. Chest 152, 120–142 (2017).
 110. Tortoli, E. et al. Isolation of the newly described species 
Mycobacterium celatum from AIDS patients. J Clin Microbiol 
33, 137–40 (1995).
 111. Piersimoni, C., Zitti, P.G., Nista, D. & Bornigia, S. 
Mycobacterium celatum pulmonary infection in the immu-
nocompetent: case report and review. Emerg Infect Dis 9, 
399–402 (2003). 
 112. Butler, W.R. et al. Mycobacterium celatum sp. nov. Int J Syst 
Bacteriol 43, 539–48 (1993). 
 113. Butler, W.R., O’Connor, S.P., Yakrus, M.A. & Gross, 
W.M. Cross-reactivity of genetic probe for detection of 
Mycobacterium tuberculosis with newly described species 
Mycobacterium celatum. J Clin Microbiol 32, 536–8 (1994). 
 114. Jun, H.J., Lee, N.Y., Kim, J. & Koh, W.J. Successful treatment 
of Mycobacterium celatum pulmonary disease in an immuno-
competent patient using antimicobacterial chemotherapy and 
combined pulmonary resection. Yonsei Med J 51, 980–983 
(2010).
 115. Aronson, J.D. Spontaneous tuberculosis in salt water fish. 
J Infect Dis 39, 315–320 (1922).
 116. Zeligman, I. Mycobacterium marinum granuloma. A disease 
acquired in the tributaries of Chesapeake Bay. Arch Dermatol 
106, 26–31 (1972).
 117. Edelstein, H. Mycobacterium marinum skin infections. 
Report of 31 cases and review of the literature. Arch Intern 
Med 154, 1359–1364 (1994).
BK-TandF-GREEN_9780367567637-200126-Chp33.indd   459 27/02/21   3:19 PM
460 Practical Handbook of Microbiology
 118. Forbes, B.A. et al. Practice guidelines for clinical microbi-
ology laboratories: mycobacteria. Clin Microbiol Rev 31, 
e00038–17 (2018).
 119. Brown-Elliott, B.A. & Philley, J.V. Rapidly growing mycobac-
teria. Microbiol Spectr 5, (2017).
 120. Griffith, D.E. & Aksamit, T.R. Nontuberculous mycobacterial 
disease therapy. Take it to the limit one more time. (Editorial). 
Chest 150, 1177–1178 (2016).
 121. Brown-Elliott, B.A. & Wallace, R.J., Jr. Clinical and taxo-
nomic status of pathogenic nonpigmented or late-pigmenting 
rapidly growing mycobacteria. Clin Microbiol Rev 15, 716–46 
(2002).
 122. Moore, M. & Frerichs, J.B. An unusual acid-fast infection 
of the knee with subcutaneous, abscess-like lesions of the 
gluteal region; report of a case with a study of the organ-
ism, Mycobacterium abscessus, n. sp. J Invest Dermatol 20, 
133–69 (1953).
 123. Lopeman, R.C., Harrison, J., Desai, M. & Cox, J.A.G. 
Mycobacterium abscessus: environmental bacterium turned 
clinical nightmare. Microorganisms 7, (2019). 
 124. Kubica, G.P. et al. Cooperative numerical-analysis of rapidly 
growing mycobacteria. J Gen Microbiol 73, 55-+ (1972).
 125. Levyfrebault, X., Grimont, F., Grimont, P.A.D. & David, 
H.L. Deoxyribonucleic-acid relatedness study of the myco-
bacterium-fortuitum-mycobacterium-chelonae complex. Int J 
System Bacteriol 36, 458–460 (1986).
 126. Cho, Y.J. et al. The genome sequence of ‘Mycobacterium 
massiliense’ strain CIP 108297 suggests the independent tax-
onomic status of the Mycobacterium abscessus complex at the 
subspecies level. PLOS One 8(11), e81560, (2013).
 127. Adekambi, T., Sassi, M., van Ingen, J. & Drancourt, M. 
Reinstating Mycobacterium massiliense and Mycobacterium 
bolletii as species of the Mycobacterium abscessus complex. 
Int J System Evol Microbiol 67, 2726–2730 (2017).
 128. Tortoli, E. et al. Emended description of Mycobacterium 
abscessus, Mycobacterium abscessus subsp abscessus and 
Mycobacterium abscessus subsp bolletii and designation of 
Mycobacterium abscessus subsp massiliense comb. nov. Int J 
System Evol Microbiol 66, 4471–4479 (2016). 
 129. Koh, W.J. et al. Clinical significance of differentiation of 
Mycobacterium massiliense from Mycobacterium abscessus. 
Am J Respir Crit Care Med 183, 405–410 (2011). 
 130. Ahmed, I., Hasan, R. & Shakoor, S. Chapter 3 Susceptibility 
Testing of Nontuberculous Mycobacteria. In: Nontuberculous 
Mycobacteria (NTM): Microbiological, Clinical and 
Geographical Distribution, Eds: Velayati, A.A. & Farnia, P. 
(Academic Press, Cambridge, MA) (2019).
 131. Lyu, J. et al. A shorter treatment duration may be sufficient for 
patients with Mycobacterium massiliense lung disease than 
with Mycobacterium abscessus lung disease. Respir Med 108, 
1706–1712 (2014).
 132. Koh, W.J., Stout, J.E. & Yew, W.W. Advances in the man-
agement of pulmonary disease due to Mycobacterium 
abscessus complex. Int J Tuberc Lung Dis 18, 1141–1148 
(2014).
 133. Kasperbauer, S.H. & De Groote, M.A. The treatment of rap-
idly growing mycobacterial infections. Clin Chest Med 36, 
67–78 (2015).
 134. Sanguinetti, M. et al. Fatal pulmonary infection due to mul-
tidrug-resistant Mycobacterium abscessus in a patient with 
cystic fibrosis. J Clin Microbiol 39, 816–819 (2001).
 135. Meyers, H. et al. An outbreak of Mycobacterium chelonae 
following liposuction. Clin Infect Dis 34, 1500–1507 (2002).
 136. Galmes-Truyols, A. et al. An outbreak of cutaneous infection 
due to Mycobacterium abscessus associated to mesotherapy. 
Enferm Infecc Microbiol Clin 29, 510–514 (2011).
 137. Stout, J.E. et al. Pedicure-associated rapidly growing myco-
bacterial infection: an endemic disease. Clin Infect Dis 53, 
787–792 (2011).
 138. Schnabel, D. et al. Multistate US outbreak of rapidly grow-
ing mycobacterial infections associated with medical tourism 
to the Dominican Republic, 2013-2014. Emerg Infect Dis 22, 
1340–1347 (2016).
 139. Sfeir, M. et al. Mycobacterium abscessus complex infections: 
a retrospective cohort study. Open Forum Infect Dis 5, ofy022 
(2018).
 140. Weber, D.J. & Rutala, W.A. Lessons from outbreaks associ-
ated with bronchoscopy. Infect Control Hosp Epidemiol 22, 
403–8 (2001).
 141. Guimaraes, T. et al. Pseudooutbreak of rapidly growing myco-
bacteria due to Mycobacterium abscessus subsp bolletii in a 
digestive and respiratory endoscopy unit caused by the same 
clone as that of a countrywide outbreak. Am J Infect Control 
44, E221–E226 (2016).
 142. Nash, K.A., Brown-Elliott, B.A. & Wallace, R.J. A novel 
gene, erm(41), confers inducible macrolide resistance to clini-
cal isolates of Mycobacterium abscessus but is absent from 
Mycobacterium chelonae. Antimicrob Agents Chemother 53, 
1367–1376 (2009).
 143. Griffith, D.E., Girard, W.M. & Wallace, R.J. Clinical features 
of pulmonary disease caused by rapidly growing mycobac-
teria. An analysis of 154 patients. Am Rev Respir Dis 147, 
1271–1278 (1993).
 144. Wallace, R.J., Brown, B.A. & Onyi, G.O. Skin, soft-tissue, and 
bone-infections due to mycobacterium-chelonae-chelonae: 
importance of prior corticosteroid-therapy, frequency of dis-
seminated infections, and resistance to oral antimicrobials 
other than clarithromycin. J Infect Dis 166, 405–412 (1992).
 145. Merlin, T.L. & Tzamaloukas, A.H. Mycobacterium chelonae 
peritonitis associated with continuous ambulatory peritoneal 
dialysis. Am J Clin Pathol 91, 717–20 (1989).
 146. Kheir, W.J., Sheheitli, H., Fattah, M.A. & Hamam, R.N. 
Nontuberculous Mycobacterial ocular infections: a systematic 
review of the literature. Biomed Res Int (2015).
 147. Meyers, H. et al. An outbreak of Mycobacterium chelonae 
infection following liposuction. Clin Infect Dis 34, 1500–1507 
(2002).
 148. Leao, S.C. et al. Practical Handbook for the Phenotypic and 
Genotypic Identification of Mycobacteria (Vanden Broele, 
Brugge, Belgium) (2004).
 149. Stanford, J.L. & Gunthorpe, W.J. Serological and bacte-
riological investigation of Mycobacterium ranae (fortuitum). 
J Bacteriol 98, 375–83 (1969).
 150. Kuster, E. Ueber kaltblutertuberkulose. Muenchener 
Medizinische Wochenschrift 57, 3 (1905).
 151. Adekambi, T. & Drancourt, M. Dissection of phylogenetic 
relationships among 19 rapidly growing Mycobacterium spe-
cies by 16S rRNA, hsp65, sodA, recA and rpoB gene sequenc-
ing. Int J Syst Evol Microbiol 54, 2095–105 (2004).
 152. Schinsky, M.F. et al. Taxonomic variation in the 
Mycobacterium fortuitum third biovariant complex: descrip-
tion of Mycobacterium boenickei sp. nov., Mycobacterium 
BK-TandF-GREEN_9780367567637-200126-Chp33.indd   460 27/02/21   3:19 PM
461The Genus Mycobacterium
houstonense sp. nov., Mycobacterium neworleansense sp. 
nov. and Mycobacterium brisbanense sp. nov. and recognition 
of Mycobacterium porcinum from human clinical isolates. Int 
J Syst Evol Microbiol 54, 1653–67 (2004).
 153. Wallace, R.J., Jr. et al. Clinical disease, drug susceptibil-
ity, and biochemical patterns of the unnamed third biovari-
ant complex of Mycobacterium fortuitum. J Infect Dis 163, 
598–603 (1991).
 154. Wallace, R.J., Jr., Brown, B.A. & Griffith, D.E. Nosocomial 
outbreaks/pseudo-outbreaks caused by nontuberculous myco-
bacteria. Annu Rev Microbiol 52, 453–490 (1998).
 155. Labombardi, V.J., O’Brien A, M. & Kislak, J.W. Pseudo-
outbreak of Mycobacterium fortuitum due to contaminated 
ice machines. Am J Infect Control 30, 184–6 (2002).
 156. Nolan, C.M., Hashisaki, P.A. & Dundas, D.F. An outbreak of 
soft-tissue infections due to Mycobacterium fortuitum asso-
ciated with electromyography. J Infect Dis 163, 1150–1153 
(1991).
 157. Hoy, J.F., Rolston, K.V.I., Hopfer, R.L. & Bodey, G.P. 
Mycobacterium fortuitum bacteremia in patients with cancer 
and long-term venous catheters. Am J Med 83, 213–217 (1987).
 158. Plemmons, R.M., McAllister, C.K., Liening, D.A. & Garces, 
M.C. Otitis media and mastoiditis due to Mycobacterium for-
tuitum: case report, review of four cases, and a cautionary 
note. Clin Infect Dis 22, 1105–6 (1996).
 159. Hector, J.S. et al. Large restriction fragment patterns of 
genomic Mycobacterium fortuitum DNA as strain-specific 
markers and their use in epidemiologic investigation of four 
nosocomial outbreaks. J Clin Microbiol 30, 1250–5 (1992).
 160. Hoffman, P.C., Fraser, D.W., Robicsek, F., O’Bar, P.R. & 
Mauney, C.U. Two outbreaks of sternal wound infection due to 
organisms of the Mycobacterium fortuitum complex. J Infect 
Dis 143, 533–42 (1981).
 161. Winthrop, K.L. et al. The clinical management and outcome 
of nail salon-acquired Mycobacterium fortuitum skin infec-
tion. Clin Infect Dis 38, 38–44 (2004).
 162. Wallace, R.J., Swenson, J.M., Silcox, V.A. & Bullen, M.G. 
Treatment of nonpulmonary infections due to Mycobacterium 
fortuitum and Mycobacterium chelonei on the basis of in vitro 
susceptibilities. J Infect Dis 152, 500–514 (1985).
 163. Swenson, J.M., Wallace, R.J., Silcox, V.A. & Thornsberry, 
C. Antimicrobial susceptibility of five subgroups of 
Mycobacterium fortuitum and Mycobacterium chelonae. 
Antimicrob Agents Chemother 28, 807–811 (1985).
 164. Naidoo, P., Dunbar, R., Caldwell, J., Lombard, C. & Beyers, 
N. Has universal screening with Xpert® MTB/RIF increased 
the proportion of multidrug-resistant tuberculosis cases diag-
nosed in a routine operational setting? PLOS One 12, e0172143 
(2017).
 165. Churchyard, G.J. et al. Xpert MTB/RIF versus sputum 
microscopy as the initial diagnostic test for tuberculosis: a 
cluster-randomised trial embedded in South African roll-
out of Xpert MTB/RIF. Lancet Glob Health 3, e450–e457 
(2015).
 166. Albert, H. et al. Development, roll-out and impact of Xpert 
MTB/RIF for tuberculosis: what lessons have we learnt and 
how can we do better? Eur Respir J 48, 516–525 (2016).
 167. World Health Organization. The use of loop-mediated isother-
mal amplification (TB-LAMP) for the diagnosis of pulmonary 
tuberculosis. Policy guidance. World Health Organization 
Document WHO/HTM/TB/2016.11, 1–39 (2016).
 168. Shete, P.B., Farr, K., Strnad, L., Gray, C.M. & Cattamanchi, 
A. Diagnostic accuracy of TB-LAMP for pulmonary tubercu-
losis: a systematic review and meta-analysis. BMC Infect Dis 
19, 268 (2019).
 169. Wang, G.R. et al. Xpert MTB/RIF Ultra improved the diagno-
sis of paucibacillary tuberculosis: a prospective cohort study. 
J Infect 78, 311–316 (2019).
 170. World Health Organization. The use of lateral flow urine lipo-
arabinomannan assay (LF-LAM) for the diagnosis and screen-
ing of active tuberculosis in people living with HIV. World 
Health Organization Document WHO/HTM/TB/2015.25, 
1–62 (2015).
 171. World Health Organization. Lateral flow urine lipoarabino-
mannan assay (LF-LAM) for the diagnosis of active tubercu-
losis in people living with HIV. Policy update. World Health 
Organization Document WHO/CDS/TB/2019.16 (2019).
 172. World Health Organization. Commercial serodiagnostic tests 
for diagnosis of tuberculosis. Expert group meeting report 
22 July 2010. World Health Organization Document WHO/
HTM/TB/2011.14, 1–66 (2011).
 173. Pai, M. & Behr, M. Latent Mycobacterium tuberculosis 
infection and interferon-gamma release assays. Microbiol 
Spectrum 4, TBTB2-0023-2016 (2016).
 174. Aggerbeck, H. et al. C-Tb skin test to diagnose Mycobacterium 
tuberculosis infection in children and HIV-infected adults: a 
phase 3 trial. PLOS One 13, e0204554 (2018).
 175. Slogotskaya, L., Bogorodskaya, E., Ivanova, D. & 
Sevostyanova, T. Comparative sensitivity of the test with 
tuberculosis recombinant allergen, containing ESAT6-CFP10 
protein, and Mantoux test with 2 TU PPD-L in newly diag-
nosed tuberculosis children and adolescents in Moscow. 
PLOS One 13, (2018).
 176. Smith, G.S. et al. Epidemiology of nontuberculous myco-
bacteria isolations among central North Carolina residents, 
2006–2010. J Infect 72, 678–686 (2016).
 177. Brown, M. et al. Prospective study of sputum induction, gas-
tric washing, and bronchoalveolar lavage for the diagnosis of 
pulmonary tuberculosis in patients who are unable to expecto-
rate. Clin Infect Dis 44, 1415–1420 (2007).
 178. GLI. Global Laboratory Initiative advancing TB diagnosis: 
GUIDE to TB Specimen Referral Systems and Integrated 
Networks. Global Laboratory Initiative Document (2018).
 179. Kordy, F. et al. Utility of gastric aspirates for diagnosing 
tuberculosis in children in a low prevalence area predic-
tors of positive cultures and significance of non-tuberculous 
Mycobacteria. Pediatr Infect Dis J 34, 91–93 (2015).
 180. Liu, R.M. et al. GeneXpert of stool versus gastric lavage fluid 
for the diagnosis of pulmonary tuberculosis in severely ill 
adults. Infection 47, 611–616 (2019).
 181. Sanoussi, C.N. et al. Storage of sputum in cetylpyridinium 
chloride, OMNIgene.SPUTUM, and ethanol is compat-
ible with molecular tuberculosis diagnostic testing. J Clin 
Microbiol 57, e00275–19 (2019).
 182. Kent, P.T. & Kubica, G.P. Public health mycobacteriology. 
A guide for the level III laboratory. Ed: U.S. Department 
of Health and Human Services, 1–207 (Centers for Disease 
Control) (1985).
 183. World Health Organization. Fluorescent light-emitting diode 
(LED) microscopy for diagnosis of tuberculosis. Policy state-
ment. World Health Organization Document WHO/HTM/
TB/2011.8, 1–12 (2011).
BK-TandF-GREEN_9780367567637-200126-Chp33.indd   461 27/02/21   3:19 PM
462 Practical Handbook of Microbiology
 184. Cohn, M.L., Waggoner, R.F. & McClatchy, J.K. The 7H11 
medium for the cultivation of mycobacteria. Am Rev Respir 
Dis 98, 295–296 (1968).
 185. Preece, C.L. et al. A novel culture medium for isolation of 
rapidly-growing mycobacteria from the sputum of patients 
with cystic fibrosis. J Cyst Fibros. 15(2), 186–191 (2016 Mar). 
doi: 10.1016/j.jcf.2015.05.002.
 186. Stephenson, D. et al. An evaluation of methods for the isola-
tion of nontuberculous mycobacteria from patients with cystic 
fibrosis, bronchiectasis and patients assessed for lung trans-
plantation. BMC Pulm Med 19, 19 (2019).
 187. Plongla, R., Preece, C.L., Perry, J.D. & Gilligan, P.H. Evaluation 
of RGM medium for isolation of nontuberculous mycobacteria 
from respiratory samples from patients with cystic fibrosis in 
the United States. J Clin Microbiol 55, 1469–1477 (2017).
 188. Sorlozano, A. et al. Comparative evaluation of three culture 
methods for the isolation of Mycobacteria from clinical sam-
ples. J Microbiol Biotechnol 19, 1259–1264 (2009).
 189. Rastogi, N., Goh, K.S. & David, H.L. Selective-inhibition 
of the mycobacterium-tuberculosis complex by P-nitro-
alpha-acetylamino-beta-hydroxypropio phenone (Nap) and 
P-nitrobenzoic acid (Pnb) used in 7h11 agar medium. Res 
Microbiol 140, 419–423 (1989).
 190. Chikamatsu, K. et al. Comparative evaluation of three immu-
nochromatographic identification tests for culture confirma-
tion of Mycobacterium tuberculosis complex. BMC Infect Dis 
14(1), 54 (2014).
 191. Orikiriza, P. et al. Evaluation of the SD Bioline TB Ag MPT64 
test for identification of Mycobacterium tuberculosis complex 
from liquid cultures in Southwestern Uganda. Af J Lab Med 6, 
(2017).
 192. Sanoussi, C.N. et al. Low sensitivity of the MPT64 identifica-
tion test to detect lineage 5 of the Mycobacterium tuberculosis 
complex. J Med Microbiol 67, 1718–1727 (2018).
 193. Ofori-Anyinam, B. et al. Impact of the Mycobacterium afri-
canum West Africa 2 Lineage on TB diagnostics in West 
Africa: decreased sensitivity of rapid identification tests in the 
Gambia. PLOS Negl Trop Dis 10, e0004801 (2016).
 194. Greco, V. et al. Applications of MALDI-TOF mass spec-
trometry in clinical proteomics. Expert Rev Proteomics 15, 
683–696 (2018).
 195. Brown-Elliott, B.A. et al. Comparison of two commercial 
matrix-assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-TOF MS) systems for identification of 
nontuberculous mycobacteria. Am J Clin Pathol 152, 527–536 
(2019).
 196. Miller, E. et al. Performance of Vitek MS v3.0 for identification 
of Mycobacterium species from patient samples by use of auto-
mated liquid systems. J Clin Microbiol 56, e00219–18 (2018).
 197. Epperson, L.E. et al. Evaluation of a novel MALDI biotyper 
algorithm to distinguish Mycobacterium intracellulare from 
Mycobacterium chimaera. Front Microbiol 9, 3140 (2018).
 198. Forero Morales, M.P., Lim, C.K., Shephard, L. & Weldhagen, 
G.F. Mycobacterial inactivation protein extraction protocol 
for matrix-assisted laser desorption ionization time-of-flight 
characterization of clinical isolates. Int J Mycobacteriol 7, 
217–221 (2018).
 199. Drancourt, M. Detection of microorganisms in blood speci-
mens using matrix-assisted laser desorption ionization time-
of-flight mass spectrometry: a review. Clin Microbiol Infect 
16, 1620–1625 (2010).
 200. Jouet A. et al. Deep amplicon sequencing for culture-
free prediction of susceptibility or resistance to 13 anti-
tuberculous drugs. Eur Respir J, 2002338 (2020). doi: 
10.1183/13993003.02338-2020.
 201. Woods, G.L. et al. Susceptibility testing of mycobacteria, 
Nocardia spp and other aerobic Actinomycetes. Clinical and 
Laboratory Standard Institute document M24–A3 (2018).
 202. Lewinsohn, D.M. et al. Official American Thoracic Society/
Infectious Diseases Society of America/Centers for Disease 
Control and Prevention clinical practice guidelines: diagno-
sis of tuberculosis in adults and children. Clin Infect Dis 64, 
111–115 (2017).
 203. Gilpin, C., Korobitsyn, A. & Weyer, K. Current tools avail-
able for the diagnosis of drug-resistant tuberculosis. Ther Adv 
Infect Dis 3, 145–151 (2016).
 204. World Health Organization. Tuberculosis laboratory biosafety 
manual. World Health Organization Document WHO/HTM/
TB/2012.11, 1–50 (2012).
 205. World Health Organization. Technical report on critical con-
centrations for drug susceptibility testing of medicines used 
in the treatment of drug-resistant tuberculosis. World Health 
Organization Document WHO/CDS/TB/2018.5, 1–106 (2018).
 206. Van Deun, A. et al. Rifampin drug resistance tests for tuber-
culosis: challenging the gold standard. J Clin Microbiol 51, 
2633–2640 (2013).
 207. World Health Organization. Technical manual for drug sus-
ceptibility testing of medicines used in the treatment of tuber-
culosis. World Health Organization Document WHO/CDS/
TB/2018.24, 1–39 (2018).
 208. Torrea, G. et al. Bedaquiline susceptibility testing of 
Mycobacterium tuberculosis in an automated liquid culture 
system. J Antimicrob Chemother 70, 2300–5 (2015).
 209. Keller, P.M. et al. Determination of MIC distribution and 
epidemiological cutoff values for bedaquiline and delama-
nid in Mycobacterium tuberculosis using MGIT 960 system 
equipped with TB eXiST. Antimicrob Agents Chemother 59, 
4352–4355 (2015). 
 210. Schena, E. et al. Delamanid susceptibility testing of 
Mycobacterium tuberculosis using the resazurin microtitre 
assay and the BACTEC MGIT 960 system. J Antimicrob 
Chemother 71, 1532–9 (2016). 
 211. Siddiqi, S. & Ruesch Gerdes, S. MGIT Procedure Manual—
Mycobacteria Growth Indicator Tube (MGIT) Culture and 
Drug Susceptibility Demonstration Projects. Foundation for 
Innovative New Diagnostics (FIND) document(2006).
 212. Rigouts, L. et al. Rifampin resistance missed in automated liq-
uid culture systems for Mycobacterium tuberculosis isolates 
with specific rpoB mutations. J Clin Microbiol 51, 2641–2645 
(2013).
 213. Miotto, P., Cabibbe, A.M., Borroni, E., Degano, M. & Cirillo, 
D.M. Role of disputed mutations in the rpoB gene in interpre-
tation of automated liquid MGIT culture results for rifampin 
susceptibility tesing of Mycobacterium tuberculosis. J Clin 
Microbiol 56, e01599–17 (2018). 
 214. Hoffner, S. et al. Proficiency of drug susceptibility testing 
of Mycobacterium tuberculosis against pyrazinamide: the 
Swedish experience. Int J Tuberc Lung Dis 17, 1486–1490 
(2013). 
 215. Ezewudo, M. et al. Integrating standardized whole genome 
sequence analysis with a global Mycobacterium tuberculosis 
antibiotic resistance knowledgebase. Sci Rep 8, 15382 (2018). 
BK-TandF-GREEN_9780367567637-200126-Chp33.indd   462 27/02/21   3:19 PM
463The Genus Mycobacterium
 216. Drobniewski, F. et al. Systematic review, meta-analysis and 
economic modelling of molecular diagnostic tests for anti-
biotic resistance in tuberculosis. Health Technol Assess 19, 
1–188, vii-viii (2015).
 217. Sahrin, M. et al. Discordance in Xpert® MTB/RIF assay 
results among low bacterial load specimens in Bangladesh. 
Int J Tuberc Lung Dis 22, 1056–1062 (2018).
 218. Ocheretina, O. et al. False-positive rifampin resistant results 
with Xpert MTB/RIF version 4 assay in clinical samples with 
a low bacterial load. Diagn Microbiol Infect Dis 85, 53–55 
(2016). 
 219. Semuto Ngabonziza, J.C. et al. Prevalence and drivers of 
false-positive rifampicin-resistant Xpert MTB/RIF results: 
a prospective observational study in Rwanda. Lancet 
Microbe, 1(2), e74–e83 (2020), https://doi.org/10.1016/
S2666-5247(20)30007-0
 220. Mathys, V., van de Vyvere, M., de Droogh, E., Soetaert, K. & 
Groenen, G. False-positive rifampicin resistance on Xpert® 
MTB/RIF caused by a silent mutation in the rpoB gene. Int J 
Tuberc Lung Dis 18, 1255–1257 (2014). 
 221. Chakravorty, S. et al. The new Xpert MTB/RIF Ultra: improv-
ing detection of Mycobacterium tuberculosis and resistance to 
rifampin in an assay suitable for point-of care testing. mBio 8, 
e00812–17 (2017). 
 222. World Health Organization. The use of molecular line probe 
assays for the detection of resistance to isoniazid and rifam-
picin.World Health Organization Document WHO/HTM/
TB/2016.12 (2016).
 223. World Health Organization. The use of molecular line probe 
assays for the detection of resistance to second-line anti-tuber-
culosis drugs.World Health Organization Document WHO/
HTM/TB/2016.07 (2016).
 224. Driesen, M. et al. Evaluation of a novel line probe assay to 
detect resistance to pyrazinamide, a key drug used for tuber-
culosis treatment. Clin Microbiol Infect 24, 60–64 (2018).
 225. Jouet, A., et al. Deep amplicon sequencing for culture-
free prediction of susceptibility or resistance to 13 anti-
tuberculous drugs. Eur Respir J, 2002338 (2020 Sep). doi: 
10.1183/13993003.02338-2020.
 226. World Health Organization. The use of next-generation 
sequencing technologies for the detection of mutations associ-
ated with drug resistance in Mycobacterium tuberculosis com-
plex: technical guide. World Health Organization Document 
WHO/CDS/TB/2018.19 (2018).
 227. Villellas, C. et al. Unexpected high prevalence of resistance-
associated Rv0678 variants in MDR-TB patients without doc-
umented prior use of clofazimine or bedaquiline. J Antimicrob 
Chemother 72, 684–690 (2017).
 228. Yang, J.S., Kim, K.J., Choi, H. & Lee, S.H. Delamanid, 
Bedaquiline, and Linezolid Minimum Inhibitory concentra-
tion distributions and resistance-related gene mutations in mul-
tidrug-resistant and extensively drug-resistant Tuberculosis in 
Korea. Ann Lab Med 38, 563–568 (2018).
BK-TandF-GREEN_9780367567637-200126-Chp33.indd   463 27/02/21   3:19 PM
BK-TandF-GREEN_9780367567637-200126-Chp33.indd   464 27/02/21   3:19 PM
